Bicyclic urea as a kinase inhibitor

Abstract

This application provides a bicyclic urea compound that modulates the activity of JAK2, which is useful in treating various diseases, including cancer.

Description

[Technical Field]

[0001] Sequence List This application includes a sequence listing submitted electronically as an XML file named "20443-0806WO1_SL_ST26.XML". This XML file, created on March 12, 2024, has a size of 2,281 bytes. The material within the XML file is incorporated herein by reference in its entirety.

[0002] The present invention provides a bicyclic urea compound that modulates JAK2 activity and is useful for treating JAK2-related diseases, including cancer. [Background technology]

[0003] Janus kinase (JAK) 2 plays a crucial role in signaling by several cytokine receptors. The JAK2 V617F variant, located in the pseudokinase (JH2) domain, is the most common molecular event associated with myeloproliferative neoplasms (MPNs). Current JAK2 small molecule inhibitors used to treat MPNs are designed to target the JAK2 kinase (JH1) domain. Therefore, selective targeting of the JAK2 V617F variant, rather than the JAK2 kinase (JH1) domain, may be useful for treating various pathological conditions while preserving essential JAK2 function. This application addresses this need and other needs. [Overview of the project]

[0004] In particular, the present invention relates to the compound of formula I, [ka] With respect to the pharmaceutically acceptable salt thereof, the constituent members are defined herein.

[0005] The present invention further provides a pharmaceutical composition comprising a compound of formula I, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0006] The present invention further provides a method for inhibiting the activity of the V617F variant of JAK2 kinase, which comprises contacting the kinase with a compound of formula I or a pharmaceutically acceptable salt thereof.

[0007] The present invention further provides a method for treating a disease or disorder associated with the expression or activity of the V617F variant of JAK2 kinase in a patient by administering to the patient a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

[0008] The present invention further provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in any of the methods described herein.

[0009] The present invention further provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in any of the methods described herein.

BEST MODE FOR CARRYING OUT THE INVENTION

[0010] This application provides a compound of formula I,

Chemical formula

[0011] In some embodiments, Cy 4 C 6~10 Selected from aryls and 5-14 member heteroaryls, Cy 4 C 6~10 Each of the aryl and 5-12 membered heteroaryls has 1, 2, 3, or 4 independently selected R 4 It can be arbitrarily substituted with substituents, However, the following conditions apply: (i)Cy 4 However, it is not triazolopyridinyl, (ii)R 5 However, not morpholinil or piperazinil, (iii) Cy 4 If R is phenyl, 5It is not pyridinyl or pyrimidinyl.

[0012] In some embodiments, Cy 4 It is selected from phenyl and 5-14 member heteroaryls, and Cy 4 The phenyl and 5-14 member heteroaryls are each independently selected from 1, 2, 3, or 4 R 4 It can be arbitrarily substituted with substituents, However, the following conditions apply: (i)Cy 4 However, it is not triazolopyridinyl, (ii)R 5 However, not morpholinil or piperazinil, (iii) Cy 4 If R is phenyl, 5 It is not pyridinyl or pyrimidinyl.

[0013] In some embodiments, Cy 4 The compounds are selected from phenyl, monocyclic 5-6 member heteroaryls, and bicyclic 8-14 member heteroaryls, and Cy 4 Phenyl, monocyclic 5-6 member heteroaryl, and bicyclic 8-14 member heteroaryl are each independently selected from 1, 2, 3, or 4 R 4 It can be arbitrarily substituted with substituents, However, the following conditions apply: (i)Cy 4 However, it is not triazolopyridinyl, (ii)R 5 However, not morpholinil or piperazinil, (iii) Cy 4 If R is phenyl, 5 It is not pyridinyl or pyrimidinyl.

[0014] In some embodiments, Cy 4The following are selected from phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridinyl-2-onyl, and pyrazolo[4,3-b]pyridinyl, Cy 4 Phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridinyl-2-onyl, and pyrazolo[4,3-b]pyridinyl are each 1, 2, 3, or 4 independently selected R 4 It can be arbitrarily substituted with substituents, However, the following conditions apply: (i)R 5 However, not morpholinil or piperazinil, (ii) Cy 4 If R is phenyl, 5 It is not pyridinyl or pyrimidinyl.

[0015] In some embodiments, Cy 4 The following are selected from phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl, and Cy 4 Phenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl are each 1, 2, 3, or 4 independently selected R 4 It can be arbitrarily substituted with substituents, However, the following conditions apply: (i)R 5 However, not morpholinil or piperazinil, (ii) Cy 4 If R is phenyl, 5 It is not pyridinyl or pyrimidinyl.

[0016] In some embodiments, Cy 4 It is phenyl, and this is 1, 2, 3, or 4 independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil, piperazinil, pyridinil, or pyrimidinil.

[0017] In some embodiments, Cy 4 The following are selected from thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl, Cy 4 Thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridinyl-2-onyl, and pyrazolo[4,3-b]pyridinyl are each 1, 2, 3, or 4 independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0018] In some embodiments, Cy 4 The following are selected from thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl, Cy 4 Thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl are each selected from 1, 2, 3, or 4 independently. 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0019] In some embodiments, Cy 4 It is selected from thiazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, Cy 4Thiazolyl, pyrazolyl, pyridinyl, and pyrimidinyl are each 1, 2, 3, or 4 independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0020] In some embodiments, Cy 4 This is thiazolyl, which is one or two independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0021] In some embodiments, Cy 4 It is pyrazolyl, which is one or two independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0022] In some embodiments, Cy 4 It is pyridinyl, which is 1, 2, 3, or 4 independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0023] In some embodiments, Cy 4 This is pyrimidinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0024] In some embodiments, Cy 4Cy 4 Quinolinyl, imidazo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[3,2-b]pyridinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridinyl-2-onyl, and pyrazolo[4,3-b]pyridinyl are each selected from 1, 2, 3, or 4 independently R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0025] In some embodiments, Cy 4 It is selected from quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl, Cy 4 The quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl are each selected from 1, 2, 3, or 4 independently. 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0026] In some embodiments, Cy 4 This is quinolinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0027] In some embodiments, Cy 4 This is imidazo[1,2-b]pyridazinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0028] In some embodiments, Cy 4 This is pyrazolo[1,5-a]pyrimidinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0029] In some embodiments, Cy 4 This is pyrrolo[3,2-b]pyridinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0030] In some embodiments, Cy 4 This is 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-onyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0031] In some embodiments, Cy 4 This is pyrazolo[4,3-b]pyridinyl, which is one, two, three, or four independently selected R 4 It can be optionally substituted with substituents, however, R 5 However, this is subject to the condition that it is not morpholinil or piperazinil.

[0032] In some embodiments, the compound of formula I is the compound of formula II: [ka] or a pharmaceutically acceptable salt thereof.

[0033] In some embodiments, the compound of formula I is the compound of formula IIa, [ka] or a pharmaceutically acceptable salt thereof, where m is 0, 1, 2, 3, 4, 5, 6, or 7.

[0034] In some embodiments, the compound of formula I is the compound of formula IIb: [ka] or a pharmaceutically acceptable salt thereof, where m is 0, 1, 2, 3, 4, 5, 6, or 7.

[0035] In some embodiments of formulas IIa and IIb, m is 0, 1, 2, 3, or 4.

[0036] In some embodiments of formulas IIa and IIb, m is 0, 1, 2, or 3.

[0037] In some embodiments of formulas IIa and IIb, m is 0, 1, or 2.

[0038] In some embodiments of formulas IIa and IIb, m is 0 or 1.

[0039] In some embodiments, the compound of formula I is the compound of formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, IIIk, IIIm, IIIn: [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0040] In some embodiments, the compound of formula I is a compound of formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, or IIIj: [ka] or a pharmaceutically acceptable salt thereof.

[0041] In some embodiments, the compound of formula I is the compound of formula IIIa, or a pharmaceutically acceptable salt thereof.

[0042] In some embodiments, the compound of formula I is the compound of formula IIIb, or a pharmaceutically acceptable salt thereof.

[0043] In some embodiments, the compound of formula I is the compound of formula IIIc, or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments, the compound of formula I is the compound of formula IIId or a pharmaceutically acceptable salt thereof.

[0045] In some embodiments, the compound of formula I is the compound of formula IIIe or a pharmaceutically acceptable salt thereof.

[0046] In some embodiments, the compound of formula I is the compound of formula IIIf, or a pharmaceutically acceptable salt thereof.

[0047] In some embodiments, the compound of formula I is the compound of formula IIIg, or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, the compound of formula I is the compound of formula IIIh or a pharmaceutically acceptable salt thereof.

[0049] In some embodiments, the compound of formula I is the compound of formula IIIi, or a pharmaceutically acceptable salt thereof.

[0050] In some embodiments, the compound of formula I is the compound of formula IIIj, or a pharmaceutically acceptable salt thereof.

[0051] In some embodiments, the compound of formula I is the compound of formula IIIk, or a pharmaceutically acceptable salt thereof.

[0052] In some embodiments, the compound of formula I is the compound of formula IIIm, or a pharmaceutically acceptable salt thereof.

[0053] In some embodiments, the compound of formula I is the compound of formula IIIn, or a pharmaceutically acceptable salt thereof.

[0054] In some embodiments, the compound of formula I is a compound of formulas IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVI, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu, or IVv: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0055] In some embodiments, the compound of formula I is the compound of formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVI, IVj, IVk, IVm, IVn, IVo: [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0056] In some embodiments, the compound of formula I is a compound of formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, or IVI: [ka] or a pharmaceutically acceptable salt thereof.

[0057] In some embodiments, the compound of formula I is the compound of formula IVa, or a pharmaceutically acceptable salt thereof.

[0058] In some embodiments, the compound of formula I is the compound of formula IVb, or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the compound of formula I is the compound of formula IVc, or a pharmaceutically acceptable salt thereof.

[0060] In some embodiments, the compound of formula I is the compound of formula IVd, or a pharmaceutically acceptable salt thereof.

[0061] In some embodiments, the compound of formula I is the compound of formula IVe, or a pharmaceutically acceptable salt thereof.

[0062] In some embodiments, the compound of formula I is the compound of formula IVf, or a pharmaceutically acceptable salt thereof.

[0063] In some embodiments, the compound of formula I is the compound of formula IVg, or a pharmaceutically acceptable salt thereof.

[0064] In some embodiments, the compound of formula I is the compound of formula IVh, or a pharmaceutically acceptable salt thereof.

[0065] In some embodiments, the compound of formula I is the compound of formula IVi, or a pharmaceutically acceptable salt thereof.

[0066] In some embodiments, the compound of formula I is the compound of formula IVj, or a pharmaceutically acceptable salt thereof.

[0067] In some embodiments, the compound of formula I is the compound of formula IVk, or a pharmaceutically acceptable salt thereof.

[0068] In some embodiments, the compound of formula I is the compound of formula IVm, or a pharmaceutically acceptable salt thereof.

[0069] In some embodiments, the compound of formula I is the compound of formula IVn, or a pharmaceutically acceptable salt thereof.

[0070] In some embodiments, the compound of formula I is the compound of formula IVo, or a pharmaceutically acceptable salt thereof.

[0071] In some embodiments, the compound of formula I is the compound of formula IVp or a pharmaceutically acceptable salt thereof.

[0072] In some embodiments, the compound of formula I is the compound of formula IVq, or a pharmaceutically acceptable salt thereof.

[0073] In some embodiments, the compound of formula I is the compound of formula IVr, or a pharmaceutically acceptable salt thereof.

[0074] In some embodiments, the compound of formula I is a compound of formula IVs or a pharmaceutically acceptable salt thereof.

[0075] In some embodiments, the compound of formula I is the compound of formula IVt, or a pharmaceutically acceptable salt thereof.

[0076] In some embodiments, the compound of formula I is the compound of formula IVu, or a pharmaceutically acceptable salt thereof.

[0077] In some embodiments, the compound of formula I is the compound of formula IVv, or a pharmaceutically acceptable salt thereof.

[0078] In some embodiments, the compound of formula I is a compound of formulas Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, VIi, Vj, Vk, Vm, or Vn: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0079] In some embodiments, the compound of formula I is the compound of formula Va, or a pharmaceutically acceptable salt thereof.

[0080] In some embodiments, the compound of formula I is the compound of formula Vb, or a pharmaceutically acceptable salt thereof.

[0081] In some embodiments, the compound of formula I is the compound of formula Vc, or a pharmaceutically acceptable salt thereof.

[0082] In some embodiments, the compound of formula I is the compound of formula Vd, or a pharmaceutically acceptable salt thereof.

[0083] In some embodiments, the compound of formula I is the compound of formula Ve, or a pharmaceutically acceptable salt thereof.

[0084] In some embodiments, the compound of formula I is the compound of formula Vf, or a pharmaceutically acceptable salt thereof.

[0085] In some embodiments, the compound of formula I is the compound of formula Vg, or a pharmaceutically acceptable salt thereof.

[0086] In some embodiments, the compound of formula I is the compound of formula Vh, or a pharmaceutically acceptable salt thereof.

[0087] In some embodiments, the compound of formula I is the compound of formula Vi, or a pharmaceutically acceptable salt thereof.

[0088] In some embodiments, the compound of formula I is the compound of formula Vj, or a pharmaceutically acceptable salt thereof.

[0089] In some embodiments, the compound of formula I is the compound of formula Vk, or a pharmaceutically acceptable salt thereof.

[0090] In some embodiments, the compound of formula I is the compound of formula Vm, or a pharmaceutically acceptable salt thereof.

[0091] In some embodiments, the compound of formula I is the compound of formula Vn, or a pharmaceutically acceptable salt thereof.

[0092] In some embodiments of the formula Va~Vn, m is 0, 1, 2, 3, or 4.

[0093] In some embodiments of the formula Va~Vn, m is 0, 1, 2, or 3.

[0094] In some embodiments of the formula Va~Vn, m is 0, 1, or 2.

[0095] In some embodiments of the formula Va~Vn, m is 0 or 1.

[0096] In some embodiments, the compound of formula I is a compound of formula VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, Vii, VIj, VIk, VIm, or VIn: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0097] In some embodiments, the compound of formula I is the compound of formula VIa, or a pharmaceutically acceptable salt thereof.

[0098] In some embodiments, the compound of formula I is the compound of formula VIb, or a pharmaceutically acceptable salt thereof.

[0099] In some embodiments, the compound of formula I is the compound of formula VIc, or a pharmaceutically acceptable salt thereof.

[0100] In some embodiments, the compound of formula I is the compound of formula VId, or a pharmaceutically acceptable salt thereof.

[0101] In some embodiments, the compound of formula I is the compound of formula VIe, or a pharmaceutically acceptable salt thereof.

[0102] In some embodiments, the compound of formula I is the compound of formula VIf, or a pharmaceutically acceptable salt thereof.

[0103] In some embodiments, the compound of formula I is the compound of formula VIg, or a pharmaceutically acceptable salt thereof.

[0104] In some embodiments, the compound of formula I is the compound of formula VIh, or a pharmaceutically acceptable salt thereof.

[0105] In some embodiments, the compound of formula I is the compound of formula VIi, or a pharmaceutically acceptable salt thereof.

[0106] In some embodiments, the compound of formula I is the compound of formula VIj, or a pharmaceutically acceptable salt thereof.

[0107] In some embodiments, the compound of formula I is the compound of formula VIk, or a pharmaceutically acceptable salt thereof.

[0108] In some embodiments, the compound of formula I is the compound of formula VIm, or a pharmaceutically acceptable salt thereof.

[0109] In some embodiments, the compound of formula I is a compound of formula VIn, or a pharmaceutically acceptable salt thereof.

[0110] In some embodiments of the formulas VIa to VIn, m is 0, 1, 2, 3, or 4.

[0111] In some embodiments of the formulas VIa to VIn, m is 0, 1, 2, or 3.

[0112] In some embodiments of equations VIa to VIn, m is 0, 1, or 2.

[0113] In some embodiments of the formulas VIa to VIn, m is 0 or 1.

[0114] In some embodiments, the compound of formula I is a compound of formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf, VIIg, VIIh, VIIi, VIIj, VIIk, VIIm, VIIn, or VIIo: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0115] In some embodiments, the compound of formula I is the compound of formula VIIa, or a pharmaceutically acceptable salt thereof.

[0116] In some embodiments, the compound of formula I is the compound of formula VIIb, or a pharmaceutically acceptable salt thereof.

[0117] In some embodiments, the compound of formula I is the compound of formula VIIc, or a pharmaceutically acceptable salt thereof.

[0118] In some embodiments, the compound of formula I is the compound of formula VIId, or a pharmaceutically acceptable salt thereof.

[0119] In some embodiments, the compound of formula I is the compound of formula VIIe or a pharmaceutically acceptable salt thereof.

[0120] In some embodiments, the compound of formula I is the compound of formula VIIf, or a pharmaceutically acceptable salt thereof.

[0121] In some embodiments, the compound of formula I is the compound of formula VIIg, or a pharmaceutically acceptable salt thereof.

[0122] In some embodiments, the compound of formula I is the compound of formula VIIh, or a pharmaceutically acceptable salt thereof.

[0123] In some embodiments, the compound of formula I is the compound of formula VIIi, or a pharmaceutically acceptable salt thereof.

[0124] In some embodiments, the compound of formula I is the compound of formula VIIj, or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments, the compound of formula I is the compound of formula VIIk, or a pharmaceutically acceptable salt thereof.

[0126] In some embodiments, the compound of formula I is the compound of formula VIIm, or a pharmaceutically acceptable salt thereof.

[0127] In some embodiments, the compound of formula I is the compound of formula VIIn, or a pharmaceutically acceptable salt thereof.

[0128] In some embodiments, the compound of formula I is the compound of formula VIIo, or a pharmaceutically acceptable salt thereof.

[0129] In some embodiments of formulas VIIa to VIIo, m is 0, 1, 2, 3, or 4.

[0130] In some embodiments of formulas VIIa to VIIo, m is 0, 1, 2, or 3.

[0131] In some embodiments of formulas VIIa to VIIo, m is 0, 1, or 2.

[0132] In some embodiments of formulas VIIa to VIIo, m is 0 or 1.

[0133] In some embodiments, the compound of formula I is a compound of formulas VIIIa, VIIIb, VIIIc, VIIId, VIIIe, VIIIf, VIIIg, VIIIh, VIIIi, VIIIj, VIIIk, VIIIm, VIIIn, or VIIIo: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0134] In some embodiments, the compound of formula I is the compound of formula VIIIa, or a pharmaceutically acceptable salt thereof.

[0135] In some embodiments, the compound of formula I is the compound of formula VIIIb, or a pharmaceutically acceptable salt thereof.

[0136] In some embodiments, the compound of formula I is the compound of formula VIIIc, or a pharmaceutically acceptable salt thereof.

[0137] In some embodiments, the compound of formula I is the compound of formula VIIId or a pharmaceutically acceptable salt thereof.

[0138] In some embodiments, the compound of formula I is the compound of formula VIIIe or a pharmaceutically acceptable salt thereof.

[0139] In some embodiments, the compound of formula I is the compound of formula VIIIf, or a pharmaceutically acceptable salt thereof.

[0140] In some embodiments, the compound of formula I is the compound of formula VIIIg, or a pharmaceutically acceptable salt thereof.

[0141] In some embodiments, the compound of formula I is the compound of formula VIIIh, or a pharmaceutically acceptable salt thereof.

[0142] In some embodiments, the compound of formula I is the compound of formula VIIIi or a pharmaceutically acceptable salt thereof.

[0143] In some embodiments, the compound of formula I is the compound of formula VIIIj, or a pharmaceutically acceptable salt thereof.

[0144] In some embodiments, the compound of formula I is the compound of formula VIIIk, or a pharmaceutically acceptable salt thereof.

[0145] In some embodiments, the compound of formula I is the compound of formula VIIIm, or a pharmaceutically acceptable salt thereof.

[0146] In some embodiments, the compound of formula I is the compound of formula VIIIn or a pharmaceutically acceptable salt thereof.

[0147] In some embodiments, the compound of formula I is the compound of formula VIIIo, or a pharmaceutically acceptable salt thereof.

[0148] In some embodiments of formulas VIIIa to VIIIo, m is 0, 1, 2, 3, or 4.

[0149] In some embodiments of formulas VIIIa to VIIIo, m is 0, 1, 2, or 3.

[0150] In some embodiments of formulas VIIIa to VIIIo, m is 0, 1, or 2.

[0151] In some embodiments of formulas VIIIa to VIIIo, m is 0 or 1.

[0152] In some embodiments of any of formulas I to VIIIo, each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected independently from, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0153] In some embodiments of any of formulas I to VIIIo, each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A It can be optionally substituted with substituents.

[0154] In some embodiments of any of formulas I to VIIIo, each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0155] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl, C 6~10 Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, ORa4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, C 6~10 Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A It can be optionally substituted with substituents.

[0156] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl, C 6~10 Independently selected from aryl and 4-10 membered heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 6~10 Each of the aryl and 4-10 membered heterocycloalkyl groups is independently selected from 1, 2, 3, or 4 R groups. 4A It can be optionally substituted with substituents.

[0157] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 8-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 8-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A It can be optionally substituted with substituents.

[0158] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6Independently selected from alkyl, phenyl, and 8-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, phenyl, and 8-10 membered heterocycloalkyl groups are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0159] In some embodiments of any of formulas I to VIIIo, each R 4 R is independently selected from fluoro, methyl, isopropyl, methoxy, morpholinylcarbonyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R 4A It can be optionally substituted with substituents.

[0160] In some embodiments of any of formulas I to VIIIo, each R 4 R is independently selected from fluoro, methyl, phenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, phenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each independently selected from 1, 2, 3, or 4 R 4A It can be optionally substituted with substituents.

[0161] In some embodiments of any of formulas I to VIIIo, R 4 C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently.4A It can be optionally substituted with substituents.

[0162] In some embodiments of any of formulas I to VIIIo, R 4 is phenyl, C 3~7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0163] In some embodiments of any of formulas I to VIIIo, R 4 These are phenyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, 5-6 member heteroaryl, and 4-7 member heterocycloalkyl groups are each independently selected from 1, 2, 3, or 4 R groups. 4A It can be optionally substituted with substituents.

[0164] In some embodiments of any of formulas I to VIIIo, R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each independently selected from 1, 2, 3, or 4 R 4A It can be optionally substituted with substituents.

[0165] In some embodiments of any of formulas I to VIIIo, each R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each one or two independently selected R 4A It can be optionally substituted with substituents.

[0166] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyl and 5-6 member heteroaryls are selected from 1, 2, 3, or 4 independently chosen R 4A It can be optionally substituted with substituents.

[0167] In some embodiments, R 4 Hello, C 1~6 Alkyl, C 1~6 Independently selected from haloalkyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl and 5-6 member heteroaryl groups are selected from 1, 2, 3, or 4 independently chosen R groups. 4A It can be optionally substituted with substituents.

[0168] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0169] In some embodiments of any of formulas I to VIIIo, each R 4 Hello, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0170] In some embodiments of any of formulas I to VIIIo, each R 4 C 1~6 It is independently selected from haloalkyl groups.

[0171] In some embodiments of any of formulas I to VIIIo, each R 4 R is independently selected from fluoro, methyl, trifluoromethyl, phenyl, pyrazolyl, tetrahydropyranyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, phenyl, pyrazolyl, tetrahydropyranyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R 4A It can be optionally substituted with substituents.

[0172] In some embodiments of any of formulas I to VIIIo, each R 4 The compounds are independently selected from fluoro, methyl, hydroxymethyl, hydroxyisopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, trifluoromethyl, cyanophenyl, pyrazolyl, tetrahydropyranyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, (difluoromethylazetidinyl)methyl, and morpholinylcarbonyl.

[0173] In some embodiments of any of formulas I to VIIIo, each R 4 The compound is independently selected from fluoro, methyl, trifluoromethyl, cyanophenyl, pyrazolyl, tetrahydropyranyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl.

[0174] In some embodiments of any of formulas I to VIIIo, R 4The compounds are independently selected from fluoro, methyl, hydroxymethyl, hydroxyisopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, cyanophenyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, and (difluoromethylazetidinyl)methyl, and morpholinylcarbonyl.

[0175] In some embodiments of any of formulas I to VIIIo, R 4 The compound is independently selected from fluoro, methyl, cyanophenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl.

[0176] In some embodiments of any of formulas I to VIIIo, R 4 It is trifluoromethyl.

[0177] In some embodiments of any of formulas I to VIIIo, each R a4 , R b4 , R c4 , and R d4 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0178] In some embodiments of any of formulas I to VIIIo, each R a4 and R c4 H and C 1~6 It is selected independently of alkyl.

[0179] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 It is selected independently of others.

[0180] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 It is selected independently of others.

[0181] In some embodiments of any of formulas I to VIIIo, each R a41 and R b41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0182] In some embodiments of any of formulas I to VIIIo, each R a41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0183] In some embodiments of any of formulas I to VIIIo, each R a41 H, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0184] In some embodiments of any of formulas I to VIIIo, each R a41 H and C 1~6 It is selected independently of alkyl.

[0185] In some embodiments of any of formulas I to VIIIo, each R b41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0186] In some embodiments of any of formulas I to VIIIo, each R b41 H, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0187] In some embodiments of any of formulas I to VIIIo, each R b41 H and C 1~6 It is selected independently of alkyl.

[0188] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0189] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 H, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0190] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 H and C 1~6 It is selected independently of alkyl.

[0191] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0192] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 H, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0193] In some embodiments of any of formulas I to VIIIo, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41H and C 1~6 It is selected independently of alkyl.

[0194] In some embodiments of any of formulas I to VIIIo, each R 4A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 It is selected independently of alkynyl and CN.

[0195] Several embodiments, each R 4A C 1~6 Haloalkyl, CN, and OR a41 It is selected independently of others.

[0196] Several embodiments, each R 4A C 1~6 Haloalkyl, CN, and OR a41 Selected independently from, Each R a41 H and C 1~6 It is selected independently of alkyl.

[0197] In some embodiments of any of formulas I to VIIIo, each R 4A C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 It is selected independently of alkynyl and CN.

[0198] In some embodiments of any of formulas I to VIIIo, each R 4A C 1~6 Alkyl, C 1~6 It is independently selected from haloalkyl and CN.

[0199] In some embodiments of any of formulas I to VIIIo, each R 4A C 1~6 It is selected independently from alkyl and CN.

[0200] In some embodiments of any of formulas I to VIIIo, each R 4A The group is independently selected from methyl, difluoromethyl, CN, OH, and methylcarbonyl.

[0201] In some embodiments of any of formulas I to VIIIo, each R 4A The component is selected independently from methyl and CN.

[0202] In some embodiments of any of formulas I to VIIIo, each R 4A is CN.

[0203] In some embodiments, R 4 C 1~6 Alkyl, C 1~6 Independently selected from haloalkyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl and 5-6 member heteroaryl groups have 1, 2, 3, or 4 R 4A Optionally substituted with substituents, Each R 4A C 1~6 Haloalkyl, CN, and OR a41 Selected independently from, Each R a41 H and C 1~6 It is selected independently of alkyl.

[0204] In some embodiments of any of formulas I to VIIIo, R 4 R is selected from methyl, ethyl, isopropyl, trifluoromethyl, and pyridinyl. 4 Each of the methyl, ethyl, isopropyl, and pyridinyl compounds is C 1~3 Haloalkyl, CN, OH, and C 1~3 One or two R selected independently of the alkoxy 4A It can be optionally substituted with substituents.

[0205] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~12Cycloalkyl, phenyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, tetrahydropyranil, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , C(O)NR w2 R w3 , C(O)R w2 , NR w3 C(O)R w2 , NR w3 C(O)OR w2 , and NR w3 S(O)2R w2 Selected from, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R 5 C 1~6 Alkyl and phenyl each have one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 The phenyl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A It is substituted with a substituent.

[0206] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~12Cycloalkyl, phenyl, triazolyl, pyrazolyl, imidazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranil, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , C(O)NR w2 R w3 , C(O)R w2 , NR w3 C(O)R w2 , NR w3 C(O)OR w2 , and NR w3 S(O)2R w2 Selected from, R 5 C 3~12 Cycloalkyl, triazolyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranil, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R 5 C 1~6 Alkyl and phenyl each have one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 The phenyl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A It is substituted with a substituent.

[0207] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~7Cycloalkyl, phenyl, triazolyl, pyrazolyl, imidazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranil, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 NHR w2 , C(O)R w2 C(O)NHR w2 , C(O)R w2 NHC(O)R w2 , NHC(O)OR w2 , and NHS(O)2R w2 Selected from, R 5 C 3~12 Cycloalkyl, triazolyl, imidazolyl, pyrazolyl, pyrrolidinyl, piperidinyl, tetrahydropyranil, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R 5 C 1~6 Alkyl and phenyl each have one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 The phenyl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A It is substituted with a substituent.

[0208] In some embodiments of any of formulas I to VIIIo, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5AIt can be optionally substituted with substituents.

[0209] In some embodiments of any of formulas I to VIIIo, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NHR w2 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0210] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~7 Cycloalkyl, phenyl, 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 1~6 Alkyl and phenyl each have one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 The phenyl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~7 Cycloalkyl, 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R5A It can be optionally substituted with substituents.

[0211] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0212] In some embodiments of any of formulas I to VIIIo, R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0213] In some embodiments of any of formulas I to VIIIo, R 5 -CH2R w1 , C 3~7 Cycloalkyl, -phenyl-R w1 ,-phenyl-R w5 Pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2Selected from, R 5 C 3~7 Cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0214] In some embodiments of any of formulas I to VIIIo, R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NR. w2 R w3 , NR w3 C(O)R w2 , NR w3 C(O)OR w2 , and NR w3 S(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0215] In some embodiments of any of formulas I to VIIIo, R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NHR. w2 NHC(O)R w2 , NHC(O)OR w2 , and NHS(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0216] In some embodiments of any of formulas I to VIIIo, R 5 C 3~7 Cycloalkyl, 5-6 member heteroaryl, NHR w2, and C(O)R w2 Selected from, R 5 C 3~7 Cycloalkyl and 5-6 membered heteroaryl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0217] In some embodiments of any of formulas I to VIIIo, R 5 These are cyclopropyl, pyrazolyl, imidazolyl, and NHR w2 , and C(O)R w2 Selected from, R 5 Cyclopropyl, pyrazolyl, and imidazolyl are each independently selected from 1, 2, 3, or 4 R 5A It can be optionally substituted with substituents.

[0218] In some embodiments of any of formulas I to VIIIo, R w1 C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A It can be optionally substituted by substituents.

[0219] In some embodiments of any of formulas I to VIIIo, R w1 C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~7 Each of the cycloalkyl and 4- to 7-membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A It can be optionally substituted by substituents.

[0220] In some embodiments of any of formulas I to VIIIo, R w1The compound is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy, and cyclopentylamino.

[0221] In some embodiments of any of formulas I to VIIIo, R w2 C 3~7 Selected from cycloalkyl, bicyclic 8-12 member heteroaryl, monocyclic 4-7 member heterocycloalkyl, and bicyclic 8-12 member heterocycloalkyl, R w2 C 3~7 Cycloalkyls, bicyclic 8-12 membered heteroaryls, monocyclic 4-7 membered heterocycloalkyls, and bicyclic 8-12 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0222] In some embodiments of any of formulas I to VIIIo, R w2 C 3~7 Selected from cycloalkyl, 4-8 membered monocyclic heterocycloalkyl, and 6-10 membered bicyclic heterocycloalkyl, R w2 C 3~7 Cycloalkyls, 4-8 membered monocyclic heterocycloalkyls, and 6-10 membered bicyclic heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0223] In some embodiments of any of formulas I to VIIIo, R w2 C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A It can be optionally substituted with substituents.

[0224] In some embodiments of any of formulas I to VIIIo, each R w2 C 3~12A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0225] In some embodiments of any of formulas I to VIIIo, each R w2 C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0226] In some embodiments of any of formulas I to VIIIo, each R w2 C 3~7 A cycloalkyl group is independently selected from 5-6 member heteroaryl groups and 4-7 member heterocycloalkyl groups, R w2 C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0227] In some embodiments of any of formulas I to VIIIo, R w2 R is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, oxazolyl, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, oxazolyl, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0228] In some embodiments of any of formulas I to VIIIo, R w2 R is selected from cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2 Cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0229] In some embodiments of any of formulas I to VIIIo, R w2R is selected from cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2 Cyclopentyl, cyclohexyl, pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranil, octahydro-2H-pyrido[1,2-a]pyradinyl, quinolinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0230] In some embodiments of any of formulas I to VIIIo, R w2 R is selected from cyclobutyl, cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2 Cyclobutyl, cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each selected from 1, 2, 3, or 4 independently R 5A It can be optionally substituted with substituents.

[0231] In some embodiments of any of formulas I to VIIIo, R w2R is selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2 Cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each selected from 1, 2, 3, or 4 independently R 5A It can be optionally substituted with substituents.

[0232] In some embodiments of any of formulas I to VIIIo, R w2 R is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranil, piperidinil, morpholinyl, pyrrolidinil, and octahydro-2H-pyrido[1,2-a]pyrazinil. w2 Cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl, and octahydro-2H-pyrido[1,2-a]pyradinyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0233] In some embodiments of any of formulas I to VIIIo, R w2 R is selected from cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranil, piperidinil, morpholinil, pyrrolidinil, and octahydro-2H-pyrido[1,2-a]pyrazine. w2 Cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl, and octahydro-2H-pyrido[1,2-a]pyradinyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0234] In some embodiments of any of formulas I to VIIIo, each R w2 R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl. w2 Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R 5A It can be optionally substituted with substituents.

[0235] In some embodiments of any of formulas I to VIIIo, each R w3 H and C 1~6 It is selected independently of alkyl.

[0236] In some embodiments of any of formulas I to VIIIo, each R w3 H is H.

[0237] In some embodiments of any of formulas I to VIIIo, each R w4 C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 The compounds are independently selected from cycloalkyl groups, 5-10 membered heteroaryl groups, and 4-10 membered heterocycloalkyl groups.

[0238] In some embodiments of any of formulas I to VIIIo, each R w4 C 1~6 Haloalkyl and C 3~7 Selected from cycloalkyl groups.

[0239] In some embodiments of any of formulas I to VIIIo, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl.

[0240] In some embodiments of any of formulas I to VIIIo, R w5 The compound is selected from cyanomethyl and hydroxymethyl.

[0241] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51 , S(O)R b51 , S(O)NR c51 R d51 S(O)2R b51 , and S(O)2NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkinyl is selected from 1, 2, 3, or 4 independently chosen R 5B It can be optionally substituted with substituents.

[0242] Several embodiments, each R 5B is OR a52 It is selected independently of others.

[0243] Several embodiments, each R a52 H, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0244] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51 , S(O)R b51 , S(O)NR c51 Rd51 S(O)2R b51 , and S(O)2NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl groups can be optionally substituted with OH groups.

[0245] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51 , S(O)R b51 , S(O)NR c51 R d51 S(O)2R b51 , and S(O)2NR c51 R d51 It is selected independently of others.

[0246] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 Selected independently from, R 5A C 1~6 Alkyl is 1, 2, 3, or 4 independently selected R 5B It can be optionally substituted with substituents.

[0247] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 Selected independently from, R 5A C 1~6 Alkyl groups can be optionally substituted with OH groups.

[0248] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 It is selected independently of others.

[0249] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl, C 2~6Alkenyl and C 2~6 Alkinyl is selected from 1, 2, 3, or 4 independently chosen R 5B It can be optionally substituted with substituents.

[0250] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkynyl groups can be arbitrarily substituted with OH groups.

[0251] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 It is selected independently of others.

[0252] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl is 1, 2, 3, or 4 independently selected R 5B It can be optionally substituted with substituents.

[0253] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A Each C 1~6 Alkyl groups can be optionally substituted with OH groups.

[0254] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 It is selected independently of others.

[0255] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 It is selected independently of others.

[0256] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, and OR a51 It is selected independently of others.

[0257] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 It is selected independently of others.

[0258] In some embodiments of any of formulas I to VIIIo, each R 5A The following are independently selected from fluoro, methyl, trideuterated methyl, fluoromethyl, difluoromethyl, trifluoromethyl, CN, hydroxy, methoxy, amino, and ethoxycarbonyl.

[0259] In some embodiments of any of formulas I to VIIIo, each R 5A The following are independently selected from fluoro, methyl, trideuterated methyl, fluoromethyl, trifluoromethyl, CN, hydroxy, methoxy, amino, and ethoxycarbonyl.

[0260] In some embodiments of any of formulas I to VIIIo, each R 5A This is independently selected from fluoromethyl and ethoxycarbonyl.

[0261] In some embodiments of any of formulas I to VIIIo, each R 5A The compound is independently selected from chloro, fluoro, methyl, hydroxyisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, and amino.

[0262] In some embodiments of any of formulas I to VIIIo, each R 5A The compound is independently selected from fluoro, methyl, trifluoromethyl, CN, methoxy, and amino.

[0263] In some embodiments of any of formulas I to VIIIo, each R 5A The compound is independently selected from fluoromethyl, trideuterated methyl, difluoromethyl, trifluoromethyl, CN, and hydroxy.

[0264] In some embodiments of any of formulas I to VIIIo, each R 5A The compound is independently selected from fluoro, methyl, trideuterated methyl, CN, and hydroxy.

[0265] In some embodiments of any of formulas I to VIIIo, each R a51 , R b51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C2~6 It is selected independently of alkinil.

[0266] In some embodiments of any of formulas I to VIIIo, each R a51 and R b51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0267] In some embodiments of any of formulas I to VIIIo, each R a51 , R b51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0268] In some embodiments of any of formulas I to VIIIo, each R a51 and R b51 H and C 1~6 It is selected independently of alkyl.

[0269] In some embodiments of any of formulas I to VIIIo, each R a51 H and C 1~6 It is selected independently of alkyl.

[0270] In some embodiments of any of formulas I to VIIIo, each R b51 H and C 1~6 It is selected independently of alkyl.

[0271] In some embodiments of any of formulas I to VIIIo, each R c51 H and C 1~6 It is selected independently of alkyl.

[0272] In some embodiments of any of formulas I to VIIIo, each R d51 H and C 1~6 It is selected independently of alkyl.

[0273] In some embodiments of any of formulas I to VIIIo, R 4 C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R a4 , R c4 , and R d4 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R 4A C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NR. w2 R w3 , NR w3 C(O)R w2 , NR w3 C(O)OR w2 , and NR w3 S(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, Each R w2 C 3~12A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51 , S(O)Rb51 , S(O)NR c51 R d51 S(O)2R b51 , and S(O)2NR c51 R d51 Selected independently from, Each R a51 , R b51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0274] In some embodiments of any of formulas I to VIIIo, Each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0275] In some embodiments of any of formulas I to VIIIo, Each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0276] In some embodiments of any of formulas I to VIIIo, each R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4Phenyl, tetrahydropyranyl, and pyrazolyl are each one or two independently selected R 4A Optionally substituted with substituents, Each R a4 and R c4 H and C 1~6 Selected independently of alkyl, Each R 4A C 1~6 It is selected independently from alkyl and CN.

[0277] In some embodiments of any of formulas I to VIIIo, R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NHR. w2 NHC(O)R w2 , NHC(O)OR w2 , and NHS(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, Each R w2 R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl. w2 Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R 5A Optionally substituted with substituents, Each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 Selected independently from, Each R a51 H and C 1~6 It is selected independently of alkyl.

[0278] In some embodiments of any of formulas I to VIIIo, R w1 This includes cyclopropyl, fluoropyrrolidinyl, morpholinyl, OR w4 , and NHR w4 Selected from, Rw4 C 1~6 Haloalkyl and C 3~7 Selected from cycloalkyl groups.

[0279] In some embodiments of any of formulas I to VIIIo, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, R a51 H and C 1~3 Selected from alkyl groups.

[0280] In some embodiments of any of formulas I to VIIIo, each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51, S(O)R b51 , S(O)NR c51 R d51 S(O)2R b51 , and S(O)2NR c51 R d51 Selected independently from, Each R a51 , R b51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0281] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 Selected independently from, Each R a51 and R b51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0282] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 Selected independently from, Each R a51 H and C 1~6 It is selected independently of alkyl.

[0283] In some embodiments of any of formulas I to VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51selected independently from each R a51 、R c51 、and R d51 is independently selected from H and C 1~6 alkyl.

[0284] In some embodiments of any of Formulas I - VIIIo, each R 5A is independently selected from halo, C 1~6 alkyl, C 1~6 haloalkyl, CN, and OR a51 and each R a51 is independently selected from H and C 1~6 alkyl.

[0285] In some embodiments, the compound of Formula I is a compound of Formula II: ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 However, triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, NR w2 R w3 , NR w3 C(O)R w2 , NR w3 C(O)OR w2 , and NR w3 S(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, Each R w2 However, C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R 5A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, NO2, OR a51 , SR a51 NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 ,OC(O)R b51, OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)2R b51 , NR c51 S(O)2NR c51 R d51 , S(O)R b51 , S(O)NR c51 R d51 S(O)2R b51 , and S(O)2NR c51 R d51 Selected independently from, Each R a51 , R b51 , R c51 , and R d51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0286] In some embodiments of formulas I and II, R 4 is phenyl, C 3~7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4AIt can be optionally substituted with substituents.

[0287] In some embodiments of formulas I and II, R 4 These are phenyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, 5-6 member heteroaryl, and 4-7 member heterocycloalkyl groups are each independently selected from 1, 2, 3, or 4 R groups. 4A It can be optionally substituted with substituents.

[0288] In some embodiments of formulas I and II, R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each independently selected from 1, 2, 3, or 4 R 4A It can be optionally substituted with substituents.

[0289] In some embodiments of formulas I and II, R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each one or two independently selected R 4A It can be optionally substituted with substituents.

[0290] In some embodiments of formulas I and II, each R a4 , R b4 , R c4 , and R d4 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0291] In some embodiments of formulas I and II, each R a4 and R c4 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0292] In some embodiments of formulas I and II, each R a4 and R c4 H and C 1~6 It is selected independently of alkyl.

[0293] In some embodiments of formulas I and II, each R a4 and R c4 H and C 1~3 It is selected independently of alkyl.

[0294] In some embodiments of formulas I and II, R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each independently selected from 1, 2, 3, or 4 R 4A Optionally substituted with substituents, Each R a4 and R c4 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0295] In some embodiments of formulas I and II, each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6It is selected independently of alkynyl and CN.

[0296] In some embodiments of formulas I and II, each R 4A C 1~6 Alkyl, C 1~6 It is independently selected from haloalkyl and CN.

[0297] In some embodiments of formulas I and II, each R 4A C 1~6 It is selected independently from alkyl and CN.

[0298] In some embodiments of formulas I and II, each R 4A C 1~3 It is selected independently from alkyl and CN.

[0299] In some embodiments of formulas I and II, each R 4A The component is selected independently from methyl and CN.

[0300] In some embodiments of formulas I and II, R 4 Phenyl, tetrahydropyranyl, pyrazolyl, OR a4 , and NR c4 C(O)OR a4 Selected from, R 4 Phenyl, tetrahydropyranyl, and pyrazolyl are each one or two independently selected R 4A Optionally substituted with substituents, Each R a4 and R c4 H and C 1~6 Selected independently of alkyl, Each R 4A C 1~6 It is selected independently from alkyl and CN.

[0301] In some embodiments of formulas I and II, R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NHR. w2NHC(O)R w2 , NHC(O)OR w2 , and NHS(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0302] In some embodiments of formulas I and II, each R w2 C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R w2 C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0303] In some embodiments of formulas I and II, each R w2 C 3~7 A cycloalkyl group is independently selected from 5-6 member heteroaryl groups and 4-7 member heterocycloalkyl groups, R w2 C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0304] In some embodiments of formulas I and II, each R w2 R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl. w2 Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R 5A It can be optionally substituted with substituents.

[0305] In some embodiments of formulas I and II, each R 5AHello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 It is selected independently of others.

[0306] In some embodiments of formulas I and II, each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 It is selected independently of others.

[0307] In some embodiments of formulas I and II, each R a51 , R b51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0308] In some embodiments of formulas I and II, each R a51 , R b51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0309] In some embodiments of formulas I and II, each R a51 , R b51 , R c51 , and R d51 H and C 1~3 It is selected independently of alkyl.

[0310] In some embodiments of formulas I and II, each R a51 and R b51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0311] In some embodiments of formulas I and II, each R a51 and R b51 H and C 1~6 It is selected independently of alkyl.

[0312] In some embodiments of formulas I and II, each R a51 and R b51 H and C 1~3 It is selected independently of alkyl.

[0313] In some embodiments of formulas I and II, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , C(O)R b51 , and C(O)OR a51 Selected independently from, Each R a51 and R b51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0314] In some embodiments of formulas I and II, each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 Selected independently from, Each R a51 H and C 1~6 It is selected independently of alkyl.

[0315] In some embodiments of formulas I and II, each R 5A This is independently selected from fluoromethyl and ethoxycarbonyl.

[0316] In some embodiments of formulas I and II, R 5 This includes triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, and NHR.w2 NHC(O)R w2 , NHC(O)OR w2 , and NHS(O)2R w2 Selected from, R 5 Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, Each R w2 R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl. w2 Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R 5A Optionally substituted with substituents, Each R 5A Hello, C 1~6 Alkyl and C(O)OR a51 Selected independently from, Each R a51 H and C 1~6 It is selected independently of alkyl.

[0317] In some embodiments, the compound of formula I is a compound of formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, or IIIj: [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 However, C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12Cycloalkyl, 5-12 member heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 However, C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 However, C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 However, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 However, CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5AHowever, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkinyl each, OR a52 and optionally substituted with 1, 2, 3, 4, 5, 6, or 7 independently selected halo groups, Each R a51 , R c51 , and R d51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R a52 However, H and C 1~6 It is selected independently of alkyl.

[0318] In some embodiments of the preceding embodiments, Each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A is halo, oxo, C1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0319] In some embodiments, the compound of formula I is a compound of formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, or IIIj: [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 However, C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NRw2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 However, C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 However, C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 However, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 However, CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0320] In some embodiments, the compound of formula I is a compound of formulas Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh, VIi, Vj, Vk, Vm, or Vn: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 However, halo, oxo, C 1~6 Alkyl, C1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A Optionally substituted with substituents, Each R a4 and R b4 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 4-6 membered heterocycloalkyls, Each R 4A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 However, H, C 1~6 Alkyl and C 1~6 Selected independently from haloalkyl groups, R 5 However, C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10Aryl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 However, C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 However, C 3~12A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 However, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 However, CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkinyl each, OR a52 and optionally substituted with 1, 2, 3, 4, 5, 6, or 7 independently selected halo groups, Each R a51 , R c51 , and R d51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6Selected independently from Alkinnil, Each R a52 However, H and C 1~6 It is selected independently of alkyl.

[0321] In some embodiments of the preceding embodiments, Each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0322] In some embodiments, the compound of formula I is a compound of formula VIa, VIb, VIc, VId, VIe, VIf, VIg, VIh, Vii, VIj, VIk, VIm, or VIn: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A Optionally substituted with substituents, Each R a4 and R b4 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 4-6 membered heterocycloalkyls, Each R 4A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 However, H, C 1~6 Alkyl and C 1~6 Selected independently from haloalkyl groups, R 5 However, C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10Aryl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6 Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 However, C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 However, C 3~12A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4 However, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 However, CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A However, halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Alkinyl each, OR a52 and optionally substituted with 1, 2, 3, 4, 5, 6, or 7 independently selected halo groups, Each R a51 , R c51 , and R d51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6Selected independently from Alkinnil, Each R a52 However, H and C 1~6 It is selected independently of alkyl.

[0323] In some embodiments of the preceding embodiments, Each R 4 is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 4A Optionally substituted with substituents, Each R 4A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl and CN are selected independently. R 5 C 1~6 Alkyl, C 3~12 Cycloalkyl, C 6~10 Aryl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 , NR w2 R w3 , C(O)R w2 , and C(O)NR w2 R w3 Selected from, R 5 C 1~6Alkyl and C 6~10 Each aryl has one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 C 6~10 The aryl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with substituents, R 5 C 3~12 Cycloalkyl, 5-12 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R w1 C 3~12 Cycloalkyl, 4-12 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted by substituents, Each R w2 C 3~12 A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, Each R w4C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, Each R 5A is halo, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0324] Several embodiments, each R 4 Hello, C 1~6 Alkyl, C 6~10 Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, C 6~10 Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A Optionally substituted with substituents, Each R a4 and R b4 H, C1~6 Alkyl, C 1~6 It is independently selected from haloalkyls and 4-6 membered heterocycloalkyls.

[0325] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 Hello, C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-6 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-6 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. 4A It can be optionally substituted with substituents.

[0326] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a4 and R b4 C 1~6 It is independently selected from alkyl and 4-6 membered heterocycloalkyl groups.

[0327] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 Hello, C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-6 member heterocycloalkyl)-C 1~6 Alkyl-, OR a4 , and C(O)R b4 Selected independently from, R 4 C 1~6 Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-6 member heterocycloalkyl)-C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups.4A Optionally substituted with substituents, In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a4 and R b4 C 1~6 It is independently selected from alkyl and 4-6 membered heterocycloalkyl groups.

[0328] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 Hello, C 1~6 Alkyl, C 6~10 Independently selected from aryl and 4-10 membered heterocycloalkyl groups, R 4 C 1~6 Alkyl, C 6~10 Each of the aryl and 4-10 membered heterocycloalkyl groups is independently selected from 1, 2, 3, or 4 R groups. 4A It can be optionally substituted with substituents.

[0329] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 Hello, C 1~6 Independently selected from alkyl, phenyl, and 8-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, phenyl, and 8-10 membered heterocycloalkyl groups are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0330] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 Hello, C 1~6 Independently selected from alkyl, phenyl, and bicyclic 8-10 member heterocycloalkyl groups, R 4 C 1~6 Alkyl, phenyl, and bicyclic 8-10 membered heterocycloalkyl groups are each selected from 1, 2, 3, or 4 independently. 4A It can be optionally substituted with substituents.

[0331] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 R is independently selected from fluoro, methyl, trideuterated methyl, isopropyl, methoxy, morpholinyl carbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R 4A It can be optionally substituted with substituents.

[0332] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 R is independently selected from fluoro, methyl, phenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, phenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each independently selected from 1, 2, 3, or 4 R 4A It can be optionally substituted with substituents.

[0333] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4A C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a41 , and C(O)R b41 It is selected independently of others.

[0334] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a41 and R b41 H and C 1~6 It is selected independently of alkyl.

[0335] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4A C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 H and C 1~6 It is selected independently of alkyl.

[0336] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4A The group is selected from methyl, difluoromethyl, trifluoromethyl, CN, OH, and methylcarbonyl.

[0337] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4A C 1~6 Alkyl, C 1~6 It is independently selected from haloalkyl and CN.

[0338] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4A is CN.

[0339] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 R is independently selected from fluoro, methyl, trideuterated methyl, isopropyl, methoxy, morpholinyl carbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R 4A Optionally substituted with substituents, Each R4A C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a41 , and C(O)R b41 Selected independently from, Each R a41 and R b41 H and C 1~6 It is selected independently of alkyl.

[0340] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 4 R is independently selected from fluoro, methyl, trideuterated methyl, isopropyl, methoxy, morpholinyl carbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl. 4 Methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R 4A Optionally substituted with substituents, Each R 4A The group is selected from methyl, difluoromethyl, trifluoromethyl, CN, OH, and methylcarbonyl.

[0341] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 4 The compound is independently selected from fluoro, methyl, cyanophenyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl.

[0342] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 5 C 1~6 Alkyl, C 3~7Cycloalkyl, phenyl, 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 3~7 Cycloalkyl, 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A Optionally substituted with substituents, R 5 C 1~6 Alkyl and phenyl each have one R w1 A substituent and one or two independently selected R which may be optionally substituted. 5A Substituting with a substituent, or R 5 The phenyl has one R w5 A substituent and one or two independently selected R which may be optionally substituted. 5A It is substituted with a substituent.

[0343] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 5 -CH2R w1 , C 3~7 Cycloalkyl, -phenyl-R w1 ,-phenyl-R w5 , 5-10 member heteroaryl, tetrahydropyranil, pyrrolidinil, piperidinil, 2,3-dihydrobenzo[b][1,4]dioxynil, 3,4-dihydro-2H-benzo[b][1,4]oxazinil, azaspiro[2,4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R5 C 3~7 Cycloalkyl, phenyl, 5-10 member heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0344] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 5 -CH2R w1 , C 3~7 Cycloalkyl, -phenyl-R w1 ,-phenyl-R w5 , 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 3~7 Cycloalkyl, phenyl, 5-10 member heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0345] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 5 -CH2R w1 , C 3~7 Cycloalkyl, -phenyl-R w1 ,-phenyl-R w5Thiazolyl, thiopheneyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, tetrahydropyranil, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 3~7 Cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanil are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0346] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R 5 -CH2R w1 , C 3~7 Cycloalkyl, -phenyl-R w1 ,-phenyl-R w5 thiazolyl, thiophenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2.4]heptanil, OR w2 NHR w2 , C(O)R w2 , and C(O)NHR w2 Selected from, R 5 C 3~7Cycloalkyl, phenyl, pyrazolyl, pyridinyl, indazolyl, quinolinyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0347] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w1 C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~7 Each of the cycloalkyl and 4- to 7-membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A It can be optionally substituted by substituents.

[0348] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w1 C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, OR w4 , and NHR w4 Selected from, R w1 C 3~7 Cycloalkyl and 4- to 7-membered heterocycloalkyl groups each have 1 or 2 independently selected R groups. 5A It can be optionally substituted by substituents.

[0349] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w1 This includes cyclopropyl, fluoropyrrolidinyl, morpholinyl, OR w4 , and NHR w4 Selected from.

[0350] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, Rw4 C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Selected from cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl.

[0351] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w4 C 1~6 Haloalkyl, C 6~10 Ariel, C 3~10 Selected from cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl.

[0352] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R w4 C 1~6 Haloalkyl and C 3~10 Selected from cycloalkyl groups.

[0353] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R w4 C 1~6 Haloalkyl and C 3~7 Selected from cycloalkyl groups.

[0354] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w1 This includes cyclopropyl, fluoropyrrolidinyl, morpholinyl, OR w4 , and NHR w4 Selected from, R w4 C 1~6 Haloalkyl and C 3~10 Selected from cycloalkyl groups.

[0355] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, Rw1 This includes cyclopropyl, fluoropyrrolidinyl, morpholinyl, OR w4 , and NHR w4 Selected from, R w4 C 1~6 Haloalkyl and C 3~7 Selected from cycloalkyl groups.

[0356] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w1 The compound is selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy, and cyclopentylamino.

[0357] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w2 C 3~7 Selected from cycloalkyl, bicyclic 8-12 member heteroaryl, monocyclic 4-7 member heterocycloalkyl, and bicyclic 8-12 member heterocycloalkyl, R w2 C 3~7 Cycloalkyls, bicyclic 8-12 membered heteroaryls, monocyclic 4-7 membered heterocycloalkyls, and bicyclic 8-12 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0358] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w2 R is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranil, piperidinil, morpholinyl, pyrrolidinil, and octahydro-2H-pyrido[1,2-a]pyrazinil. w2 Cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, pyrrolidinyl, and octahydro-2H-pyrido[1,2-a]pyradinyl are each 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0359] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl.

[0360] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a51 , R b51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0361] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a51 H and C 1~6 It is selected independently of alkyl.

[0362] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a51 H and C 1~3 It is selected independently of alkyl.

[0363] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R a51 C 1~3 It is alkyl.

[0364] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w5 is CN or OR a51 C is replaced by 1~6 It is alkyl, R a51 H and C 1~3 Selected from alkyl groups.

[0365] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, R w5 The compound is selected from cyanomethyl and hydroxymethyl.

[0366] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Each R selected independently from 5A Selected independently from, C 1~6 The alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. 5B It can be optionally substituted with substituents.

[0367] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl is 1, 2, 3, or 4 independently selected R 5B It can be optionally substituted with substituents.

[0368] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl is one or two independently selected R 5B It can be optionally substituted with substituents.

[0369] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5B Hello, C 1~6 Alkyl, C 1~6 It is independently selected from haloalkyl and OH groups.

[0370] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5B This is selected independently of OH and halo.

[0371] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5B It is OH.

[0372] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Each R selected independently from 5A Selected independently from, C 1~6 The alkyl group is optionally substituted with an OH group and 1, 2, 3, 4, 5, 6, or 7 independently selected halo groups.

[0373] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl groups can be optionally substituted with OH groups.

[0374] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 It is selected independently of others.

[0375] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl is one or two independently selected R 5B Optionally substituted with substituents, Each R a51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0376] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, OR a51 , and NR c51 R d51 Selected independently from, R 5A C 1~6 Alkyl groups can be optionally substituted with OH groups. Each R a51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0377] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, ORa51 , and NR c51 R d51 Selected independently from, Each R a51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0378] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A The compound is independently selected from chloro, fluoro, methyl, hydroxyisopropyl, hydroxyhexafluoroisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, ethoxy, and amino.

[0379] In some embodiments of formulas I, IIIa to IIIn, Va to Vn, and VIa to VIn, each R 5A The compound is independently selected from chloro, fluoro, methyl, hydroxyisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, and amino.

[0380] In some embodiments, the compound of formula I is a compound of formulas IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVI, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu, or IVv: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A Optionally substituted with substituents, Each R 4A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 However, C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 However, C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each Rw3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0381] In some embodiments, the compound of formula I is a compound of formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, IVI, IVj, IVk, IVm, IVn, or IVO: [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A Optionally substituted with substituents, Each R 4A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 However, C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 However, C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and ORa51 Selected independently from, Each R a51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0382] In some embodiments of the preceding embodiments, Each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyl and 5-6 member heteroaryls are selected from 1, 2, 3, or 4 independently chosen R 4A Optionally substituted with substituents, Each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0383] In some embodiments, the compound of formula I is a compound of formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh, or IVI: [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A Optionally substituted with substituents, Each R 4A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 However, C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 However, C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R5A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0384] In some embodiments of the preceding embodiments, Each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A Hello, C1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0385] In some embodiments, the compound of formula I is a compound of formula VIIa, VIIb, VIIc, VIId, VIIe, VIIf, VIIg, VIIh, VIIi, VIIj, VIIk, VIIm, VIIn, or VIIo: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4AOptionally substituted with substituents, Each R 4A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 However, C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 However, C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 However, H, C 1~6Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0386] In some embodiments of the preceding embodiments, Each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyl and 5-6 member heteroaryls are selected from 1, 2, 3, or 4 independently chosen R 4A Optionally substituted with substituents, Each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0387] In some embodiments, the compound of formula I is a compound of formulas VIIIa, VIIIb, VIIIc, VIIId, VIIIe, VIIIf, VIIIg, VIIIh, VIIIi, VIIIj, VIIIk, VIIIm, VIIIn, or VIIIo: [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof, in the formula: Each R 4 But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A Optionally substituted with substituents, Each R 4A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 However, C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NR w2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 However, C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 However, H, C 1~6 Alkyl, C 1~6Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 However, H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0388] In some embodiments of the preceding embodiments, Each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Independently selected from alkynyls and 5-6 member heteroaryls, R 4 Each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyl and 5-6 member heteroaryls are selected from 1, 2, 3, or 4 independently chosen R 4A Optionally substituted with substituents, Each R 4A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a41 Selected independently from, Each R a41 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 Selected independently from Alkinnil, R 5 C 3~12 Cycloalkyl, 5-12 membered heteroaryl, NRw2 R w3 , and C(O)R w2 Selected from, R 5 C 3~12 Cycloalkyl and 5-12 membered heteroaryls are each selected from 1, 2, 3, or 4 independently. 5A Optionally substituted with substituents, Each R w2 C 3~12 Selected independently from cycloalkyl and 4-12 member heterocycloalkyl groups, R w2 C 3~12 Each of the cycloalkyl and 4-12 membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. 5A Optionally substituted with substituents, Each R w3 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, or C 2~6 Selected independently from Alkinnil, Each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN and OR a51 Selected independently from, Each R a51 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0389] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C1~6 Alkyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A It can be optionally substituted with substituents.

[0390] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4A C 1~6 Haloalkyl, CN, and OR a41 It is selected independently of others.

[0391] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R a41 H and C 1~6 It is selected independently of alkyl.

[0392] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Selected independently of alkyl-, R 4 Each C 1~6 Alkyl, C 3~7 Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C 3~7 Cycloalkyl-C 1~6 Alkyl- is one, two, three, or four independently selected R 4A Optionally substituted with substituents, Each R 4A C 1~6 Haloalkyl, CN, and OR a41 Selected independently from, Each R a41H and C 1~6 It is selected independently of alkyl.

[0393] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R 4 R is selected from methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterated tetrahydropyranyl, pyridinyl, and cyclopropylmethyl. 4 Each of the following is methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterated tetrahydropyranyl, pyridinyl, and cyclopropylmethyl, C 1~3 Haloalkyl, CN, OH, and C 1~3 One or two R selected independently of the alkoxy 4A It can be optionally substituted with substituents.

[0394] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4 Hello, C 1~6 Alkyl and C 1~6 It is independently selected from haloalkyl groups.

[0395] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4 C 1~6 It is independently selected from haloalkyl groups.

[0396] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4 C 1~3 It is independently selected from haloalkyl groups.

[0397] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 4It is trifluoromethyl.

[0398] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R 5 C 3~7 Cycloalkyl, 5-6 member heteroaryl, NHR w2 , and C(O)R w2 Selected from, R 5 C 3~7 Cycloalkyl and 5-6 membered heteroaryl are each selected from 1, 2, 3, or 4 independently. 5A It can be optionally substituted with substituents.

[0399] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R 5 These include cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, pyridinyl, and NHR. w2 , and C(O)R w2 Selected from, R 5 Cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, and pyridinyl are each independently selected from 1, 2, 3, or 4 R 5A It can be optionally substituted with substituents.

[0400] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R 5 These are cyclopropyl, pyrazolyl, imidazolyl, and NHR w2 , and C(O)R w2 Selected from, R 5 Cyclopropyl, pyrazolyl, and imidazolyl are each independently selected from 1, 2, 3, or 4 R 5A It can be optionally substituted with substituents.

[0401] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R w2 C 3~7Selected from cycloalkyl, 4-8 membered monocyclic heterocycloalkyl, and 6-10 membered bicyclic heterocycloalkyl, R w2 C 3~7 Cycloalkyls, 4-8 membered monocyclic heterocycloalkyls, and 6-10 membered bicyclic heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 5A It can be optionally substituted with substituents.

[0402] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, R w2 R is selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, w2 Cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each selected from 1, 2, 3, or 4 independently R 5A It can be optionally substituted with substituents.

[0403] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, and OR a51 It is selected independently of others.

[0404] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R a51 , R b51 , R c51 , and R d51 H and C 1~6 It is selected independently of alkyl.

[0405] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R a51 H and C 1~6 It is selected independently of alkyl.

[0406] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R a51 H and C 1~3 It is selected independently of alkyl.

[0407] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 5A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, CN, and OR a51 Selected independently from, Each R a51 H and C 1~6 It is selected independently of alkyl.

[0408] In some embodiments of formulas I, IVa-IVv, VIIa-VIIo, and VIIIa-VIIIo, each R 5A The compound is independently selected from fluoro, methyl, trideuterated methyl, CN, and hydroxy.

[0409] In some embodiments of any of formulas I to VIIIo, R 1 R is one, two, or three independently selected Rs. 1A C which can be arbitrarily substituted with substituents 1~6 It is alkyl.

[0410] In some embodiments of any of formulas I to VIIIo, R 1 C 1~6 It is alkyl.

[0411] In some embodiments of any of formulas I to VIIIo, R 1 C 1~3It is alkyl.

[0412] In some embodiments of any of formulas I to VIIIo, R 1 It is methyl or methyl trideuteride.

[0413] In some embodiments of any of formulas I to VIIIo, R 1 It is methyl.

[0414] In some embodiments of any of formulas I to VIIIo, R 1 It is methyl trideuteride.

[0415] In some embodiments of any of formulas I to VIIIo, Cy 2 This is a single ring C 3~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, bicyclic C 6~10 Selected from cycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, bicyclic C 6~10 Cycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 It is substituted with a substituent.

[0416] In some embodiments of any of formulas I to VIIIo, Cy 2 This is a single ring C 3~10 Cycloalkyl, spirocyclic C 6~10 Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, spirocyclic C 6~10Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 It is substituted with a substituent.

[0417] In some embodiments of any of formulas I to VIIIo, Cy 2 This is selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil, Cy 2 Cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl are each one, two, three, or four independently selected R 2 It can be optionally substituted by substituents.

[0418] In some embodiments of any of formulas I to VIIIo, Cy 2 Cy is selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl. 2 Cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl are each one, two, three, or four independently selected R 2 It can be optionally substituted by substituents.

[0419] In some embodiments of any of formulas I to VIIIo, Cy 2 Cy is selected from cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azabispiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil. 2 Cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azabispiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil are each one, two, three, or four independently selected R 2 It can be optionally substituted by substituents.

[0420] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from, In the formula, n is 0, 1, or 2.

[0421] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from, In the formula, n is 0, 1, or 2.

[0422] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from, In the formula, n is 0, 1, or 2.

[0423] In some embodiments of any of formulas I to VIIIo, Cy2 teeth, [ka] [ka] Selected from.

[0424] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from.

[0425] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] [ka] Selected from.

[0426] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from.

[0427] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from.

[0428] In some embodiments of any of formulas I to VIIIo, Cy 2 teeth, [ka] Selected from.

[0429] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O)2R b2 , S(O)R b2 , S(O)NR c2 R d2 S(O)2R b2 , and S(O)2NR c2 R d2 Selected independently from, R 2 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Each alkynyl is selected independently from 1, 2, 3, or 4 R 2A It can be optionally substituted with substituents.

[0430] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, CN, OR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2Rb2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0431] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0432] In some embodiments of any of formulas I to VIIIo, each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0433] In some embodiments of any of formulas I to VIIIo, each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0434] In some embodiments of any of formulas I to VIIIo, each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 2~6 Alkinyl, phenyl, C 3~7 A cycloalkyl group is independently selected from 5-6 member heteroaryl groups and 4-7 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, phenyl, C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0435] In some embodiments of any of formulas I to VIIIo, each R a2 , R b2 , Rc2 , and R d2 R is independently selected from H, methyl, trideuterated methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. a2 , R b1 , R c2 , and R d2 Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0436] In some embodiments of any of formulas I to VIIIo, each R a2 , R b2 , R c2 , and R d2 R is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. a2 , R b1 , R c2 , and R d2 Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0437] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , Rc2 , and R d2 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0438] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R a2 , Rb1 , R c2 , and R d2 C 1~6 Alkyl, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0439] In some embodiments of any of formulas I to VIIIo, each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 2~6 Alkinyl, phenyl, C 3~7 A cycloalkyl group is independently selected from 5-6 member heteroaryl groups and 4-7 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, phenyl, C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A It can be optionally substituted with substituents.

[0440] In some embodiments of any of formulas I to VIIIo, each R2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 R is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. a2 , R b1 , R c2 , and R d2 Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each one or two independently selected R 2A It can be optionally substituted with substituents.

[0441] In some embodiments of any of formulas I to VIIIo, each R 2A Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a21 Selected independently from, R 2A C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Each alkynyl is selected independently from 1, 2, 3, or 4 R 2B It can be optionally substituted with substituents.

[0442] In some embodiments of any of formulas I to VIIIo, each R 2A Hello, C 1~6 Alkyl, C1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a21 It is selected independently of others.

[0443] In some embodiments of any of formulas I to VIIIo, each R 2A This is a halo and OR a21 It is selected independently of others.

[0444] In some embodiments of any of formulas I to VIIIo, each R a21 , R b21 , R c21 , and R d21 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0445] In some embodiments of any of formulas I to VIIIo, each R a21 , R b21 , R c21 , and R d21 H and C 1~6 It is selected independently of alkyl.

[0446] In some embodiments of any of formulas I to VIIIo, each R a21 , R b21 , R c21 , and R d21 H and C 1~3 It is selected independently of alkyl.

[0447] In some embodiments of any of formulas I to VIIIo, each R a21 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl and C 2~6 It is selected independently of alkinil.

[0448] In some embodiments of any of formulas I to VIIIo, each Ra21 H and C 1~6 It is selected independently of alkyl.

[0449] In some embodiments of any of formulas I to VIIIo, each R a21 H and C 1~3 It is selected independently of alkyl.

[0450] In some embodiments of any of formulas I to VIIIo, each R a21 The element is selected independently from H and methyl.

[0451] In some embodiments of any of formulas I to VIIIo, each R 2A This is a halo and OR a21 Selected independently from, Each R a21 H and C 1~6 It is selected independently of alkyl.

[0452] In some embodiments of any of formulas I to VIIIo, each R 2A The compound is independently selected from fluoro, hydroxy, and methoxy compounds.

[0453] In some embodiments of any of formulas I to VIIIo, each R 2A The component is selected independently from fluoro and methoxy.

[0454] In some embodiments of any of formulas I to VIIIo, R 3 H and C 1~6 Selected from alkyl groups.

[0455] In some embodiments of any of formulas I to VIIIo, R 3 H and C 1~3 Selected from alkyl groups.

[0456] In some embodiments of any of formulas I to VIIIo, R 3 H is H.

[0457] In some embodiments of any of formulas I to VIIIo, R 1 C 1~6 Alkyl, C 2~6 Alkenyl and C 2~6 Selected from Alkinil, Cy 2 This is a single ring C 3~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, bicyclic C 6~10 Selected from cycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, bicyclic C 6~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 Substituting with substituents, Each R 2 Hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, OR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , NR c2 C(O)NR c2 R d2 , NR c2 S(O)R b2 , NR c2 S(O)2R b2 , S(O)R b2 , S(O)NR c2 R d2 S(O)2R b2 , and S(O)2NR c2 Rd2 Selected independently from, R 2 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Each alkynyl is selected independently from 1, 2, 3, or 4 R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 6~10 Ariel, C 3~10 Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A Optionally substituted with substituents, Each R 2A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a21 Selected independently from, Each R a21 H and C 1~6 Selected independently of alkyl, R 3 H and C 1~6 Selected from alkyl groups.

[0458] In some embodiments of the preceding embodiments, Cy 2 This is a single ring C 3~10Cycloalkyl, spirocyclic C 6~10 Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 It is substituted with a substituent.

[0459] In some embodiments of any of formulas I to VIIIo, R 1 C 1~6 Selected from alkyl groups, Cy 2 This is a single ring C 3~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, bicyclic C 6~10 Selected from cycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, bicyclic C 6~10 Cycloalkyl, spirocyclic C 6~10 Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 Substituting with substituents, Each R 2 Hello, C 1~6 Alkyl, CN, OR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 H, C 1~6 Alkyl, C 2~6 Alkinyl, phenyl, C 3~7 A cycloalkyl group is independently selected from 5-6 member heteroaryl groups and 4-7 member heterocycloalkyl groups, R a2 , R b1 , R c2 , and R d2 C 1~6 Alkyl, phenyl, C 3~7 Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. 2A Optionally substituted with substituents, Each R 2A But, hello, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, CN, and OR a21 Selected independently from, Each R a21 H and C 1~6 Selected independently of alkyl, R 3 H is H.

[0460] In some embodiments of the preceding embodiments, Cy 2 This is a single ring C 3~10 Cycloalkyl, spirocyclic C 6~10 Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, monocyclic C 3~10 Cycloalkyl, spirocyclic C 6~10Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R 2 Substituting with substituents, Each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0461] In some embodiments of any of formulas I to VIIIo, R 1 C 1~3 It is alkyl, Cy 2 This is selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil, Cy 2 Cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl are each one, two, three, or four independently selected R 2 Optionally substituted by substituents, Each R 2 Hello, C 1~6 Alkyl, CN, ORa2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 R is independently selected from H, methyl, trideuterated methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. a2 , R b1 , R c2 , and R d2 Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R 2A This is a halo and OR a21 Selected independently from, Each R a21 H and C 1~6 Selected independently of alkyl, R 3 H is H.

[0462] In some embodiments of the preceding embodiments, Cy 2 Cy is selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl. 2Cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranyl, spiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, and 2-azabicyclo[2.2.1]heptanyl are each one, two, three, or four independently selected R 2 Optionally substituted by substituents, Each R 2 Hello, C 1~6 Alkyl, CN, C(O)R b2 , C(O)OR a2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 S(O)2R b2 Selected independently from, R 2 C 1~6 Each alkyl group consists of 1, 2, 3, or 4 independently selected R 2A Optionally substituted with substituents, Each R a2 , R b2 , R c2 , and R d2 R is independently selected from H, methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl. a2 , R b1 , R c2 , and R d2 Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R 2A It can be optionally substituted with substituents.

[0463] In some embodiments, the compounds provided herein are 2-((3'-cyano-5-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-[1,1'-biphenyl]-3-yl)amino)oxazole-5-carboxylate ethyl, ((1R,3R)-3-(6-((3'-Cyano-5-(4-Fluorotetrahydro-2H-pyran-4-carboxamide)-[1,1'-biphenyl]-3-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((4-(1-methyl-1,6-diazaspiro[3,3]heptan-6-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-(hydroxymethyl)-3-methylphenyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6'-Methoxy-[2,3'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)carbamate methyl, ((1R,3R)-3-(6-((4-(4-cyanopiperidine-1-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(3-methyl-1H-indazole-5-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(quinoline-6-yl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(1-hydroxy-3-azabicyclo[3.1.0]hexane-3-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-oxa-5-azabicyclo[2.2.1]heptan-5-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-oxa-5-azabicyclo[4.1.0]heptan-5-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-1,2,3-triazole-4-yl)phenyl)carbamate methyl, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methylpiperidine-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((4-(3,3-difluoropiperidine-1-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((R)-2,2-difluorocyclopropane-1-carboxamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-((3,3-difluorocyclopentyl)amino)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate methyl, ((1R,3R)-3-(6-((3-(cyclobutanecarboxamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((6-(1-methyl-1H-pyrazole-4-yl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(tetrahydro-2H-pyran-3-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((6-((4-cyanocyclohexyl)oxy)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(quinoline-6-yloxy)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1r,3r)-3-(cyclopropanecarboxamide)cyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)carbamate methyl, (3-((1-(6-((ethoxycarbonyl)amino)spiro[3.3]heptan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)carbamate methyl, (3-((1-(6-(cyclopropanesulfonamide)spiro[3.3]heptan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, 6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-2-azaspiro[3.3]heptan-2-carboxylate methyl, (3-((1-((1r,3r)-3-cyanocyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (3-((1-((1r,3r)-3-((methoxycarbonyl)amino)-3-methylcyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)carbamate methyl, (R)-(3-((1-(3,3-difluorocyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)carbamate methyl, (3-((1-((1R,3S)-3-fluorocyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(1-methyl-1H-pyrazole-4-yl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((8-(1-methyl-1H-pyrazole-4-yl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-pyrazole-4-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((2-(1-methyl-1H-pyrazole-4-yl)pyrazolo[1,5-a]pyrimidine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-pyrazole-4-yl)pyrazolo[1,5-a]pyrimidine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-((tetrahydro-2H-pyran-4-yl)oxy)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-imidazole-5-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (1R,5S)-6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-3-azabicyclo[3.1.0]hexane-3-carboylate methyl, (3-((1-(2-acetyl-2-azabicyclo[2.2.1]heptan-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((3-((3,3-difluorocyclobutane)-1-sulfonamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-(4-((methoxycarbonyl)amino)-4-methylcyclohexyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate 2-methoxyethyl, ((1R,3R)-3-(6-((3-(cyclobutoxycarbonyl)amino)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclobutyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate ethyl, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate propane-2-in-1-yl, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)tetrahydro-2H-pyran-4-yl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate 4-fluorophenyl, ((1R,3R)-3-(6-((6-cyclopropylpyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(3-cyanophenyl)-4-(1-methyl-1H-pyrazole-4-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-cyclopropylimidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclopropoxycarbonyl)amino)-5-methoxyphenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(cyclopropanecarboxamide)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((8-(1-methylcyclopropyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(3-fluoro-1-(methyl-d3)-1H-pyrazole-4-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(cyclobutoxymethyl)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(3-aminopyrrolidin-1-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-((cyclopentylamino)methyl)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate methyl, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-(piperidine-1-yl)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2'-Methoxy-4-methyl-[2,4'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((4-(pyridine-4-yl)thiazol-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-fluoro-6'-(trifluoromethyl)-[2,3'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(((S)-3-fluoropyrrolidine-1-yl)methyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-(cyanomethyl)phenyl)-5-fluoropyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-cyclopropylphenyl)-5-fluoropyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((5-fluoro-6-(4-(trifluoromethoxy)phenyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(morpholinomethyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(2-methoxypyridine-4-yl)pyrimidine-4-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(octahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(5-Azaspiro[2,4]heptan-5-yl)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(3,3-difluoropyrrolinidine-1-yl)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-(4-(trifluoromethyl)piperidine-1-yl)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-((R)-3-fluoropyrrolidine-1-carbonyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((1-(pyridine-4-yl)-1H-pyrazole-3-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-((3,3-difluorocyclopentyl)amino)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(3,3-difluoropyrrolidine-1-yl)-6-methylpyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(piperidine-1-carbonyl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate methyl, and ((1R,3R)-3-(6-((6-(cyclohexylcarbamoyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, or selected from a pharmaceutically acceptable salt thereof.

[0464] In some embodiments, this application is, (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)cyclobutyl carbamate, (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-cyclopropyl-1H-pyrazole-4-yl)phenyl)cyclobutyl carbamate, (3-(1-cyclopropyl-1H-pyrazole-4-yl)-5-((3-methyl-2-oxo-1-(tetrahydrofuran-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)phenyl)cyclobutyl carbamate, ((1R,3R)-3-(6-((1-(2-methoxyethyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-1-methyl-2-oxo-7-(4-(trifluoromethyl)pyridine-3-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-(6-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)spiro[3,3]heptan-2-yl)cyclopropanecarboxamide, N-((1s,4s)-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclohexyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(1-methyl-1H-pyrazole-4-yl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((8-(2-cyanopropan-2-yl)-4-(morpholine-4-carbonyl)quinoline-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-3-d)methyl carbamate, ((1R,3R)-3-(6-((5-Methoxy-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-((3-(difluoromethyl)azetidine-1-yl)methyl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-cyclobutoxy-5-(1-methyl-1H-pyrazole-4-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(5-(difluoromethyl)thiophen-2-yl)-6-(hydroxymethyl)pyrimidine-4-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(difluoromethyl)thiophen-2-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(1-acetylpiperidine-4-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, 6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-1-((1r,3r)-3-(2-hydroxypropan-2-yl)cyclobutyl)-3-(methyl-d3)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(1-methyl-1H-pyrazole-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-2-oxo-6-((6-(4-(trifluoromethyl)-1H-pyrazole-1-yl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl-4-d)-3-(1(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-(1-cyanocyclopropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-7-(2-hydroxypropan-2-yl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1R,3R)-1-methyl-3-(3-(methyl-d3)-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((7-(hydroxymethyl)-2-methyl-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, N-((1s,4s)-4-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((2-((1s,3s)-3-hydroxycyclobutyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1s,4s)-4-(6-((1-((1r,4r)-4-hydroxycyclohexyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide, N-((1s,4s)-1-methyl-4-(3-(methyl-d3)-6-((2-methyl-7-(morpholine-4-carbonyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclohexyl)cyclopropanecarboxamide, ((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((3R)-3-(6-((7-(2-hydroxypropan-2-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((4-(2-hydroxypropan-2-yl)-1-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[2,3-b]pyridine-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(3-(methyl-d3)-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((2-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((6-methyl-4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-N-(methyl-d3)bicyclo[2.2.2]octane-1-carboxamide, N-Cyclopropyl-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octane-1-carboxamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octane-1-carboxamide, N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octan-1-yl)acetamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.1]heptan-1-carboxamide, N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.1]heptan-1-yl)acetamide, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)propionamide, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)thiazole-2-yl)-4-(2-hydroxypropan-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((1R,3R)-3-(6-((6-(5-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)thiazole-2-yl)-4-(2-hydroxypropan-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((5-fluoro-6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(methyl-d3)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-isopropoxythiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-methoxythiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, N-((1S,3R)-3-(6-((6-(2-ethoxythiazole-5-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((1R,3R)-3-(6-((6'-(5-(difluoromethyl)thiophen-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1S,2S,4S)-2-hydroxy-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-3-d)methyl carbamate, ((1R,3R)-3-(3-(methyl-d3)-6-((4-(1-methylpiperidine-4-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(1-methylpiperidine-4-yl)pyridine-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-2-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)-1-methylcyclopentyl)acetamide, and methyl ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-(2-hydroxypropan-2-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate a compound selected from, or a pharmaceutically acceptable salt thereof.

[0465] It is further understood that certain features of the invention, which are described in the context of separate embodiments for clarity, may also be provided in combination in a single embodiment. Conversely, the various features of the invention that are described in relation to a single embodiment for brevity can also be provided separately or in any suitable partial combination.

[0466] At various places in this specification, divalent linking substituents are described. Each divalent linking substituent is specifically intended to include both the forward and the backward forms of the linking substituent. For example, -NR(CR’R’’) n - is intended to include both -NR(CR’R’’) n - and -(CR’R’’) n NR-. When the structure requires the linking group to be specified, the Markush variables listed for that group are understood to be the linking group.

[0467] [[ID=二十一]] The term "n-membered," where n is an integer, typically refers to the number of ring-forming atoms at a site where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydronaphthalene is an example of a 10-membered cycloalkyl group.

[0468] As used herein, the phrase "optionally substituted" means either unsubstituted or substituted. Substituents are independently selected, and substitutions may be at any chemically accessible position. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced with a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms. It should be understood that substitutions at a given atom are limited by their valence.

[0469] As used herein, the phrase "each 'variable' is independently selected from..." is substantially equivalent to "in each instance, 'variable' is selected from...".

[0470] Throughout the definition, "C n-m The term "C" indicates a range including the endpoint, where n and m are integers and represent the number of carbon atoms. For example, C 1-3 , C 1-4 , C 1-6 These are some examples.

[0471] When used herein, "C" is used alone or in combination with other terms. n-mThe term "alkyl" refers to a saturated hydrocarbon group having n to m carbon atoms, which may be linear or branched. Examples of alkyl groups include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (iPr), n-butyl, tert-butyl, isobutyl, and sec-butyl, and higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, and 1,2,2-trimethylpropyl. In some embodiments, the alkyl group contains 1 to 6 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. n~m The term “alkyl” is understood to include deuterated analogs of alkyl groups as defined herein, including, but not limited to, groups such as methyl trideuterated (CD3) and ethyl pentadeuterated (CD2CD3).

[0472] When used herein, "C n-m An "alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds and containing n to m carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, etc. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. n~m The term “alkenyl” is understood to include deuterated analogs of alkenyl groups as defined herein, including, but not limited to, groups such as trideuterated ethenyl (-CD=CD2) and tetradeuterated propenyl (-CD=CD-CD2).

[0473] When used herein, "C n-m "Alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds and containing n to m carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl and propynyl (e.g., propyne-1-yl, propyne-2-yl, propa-2-in-1-yl). In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.n~m The term “alkynyl” is understood to include deuterated analogs of alkynyl groups as defined herein, including, but not limited to, groups such as deuterated ethynyl (-C≡CD) and trideuterated propyne-1-yl (-C≡CCD3).

[0474] When used herein, "C" is used alone or in combination with other terms. n-m The term "alkoxy" refers to a group of the formula -O-alkyl, where the alkyl group has n to m carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tert-butoxy), etc. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. n~m The term “alkoxy” is understood to include deuterated analogs of the alkyl moiety of an alkoxy group as defined herein, including, but not limited to, groups such as trideuterated methoxy(-OCD3) and pentadeuterated ethoxy(-OCD2CD3).

[0475] As used herein, the term "amino" refers to the group of formula -NH2.

[0476] As used herein, the term “aryl,” when used alone or in combination with other terms, refers to an aromatic hydrocarbon group that may be monocyclic or polycyclic (for example, having two, three, or four fused rings). n-mThe term "aryl" refers to an aryl group having n to m ring carbon atoms. Examples of aryl groups include phenyl, naphthyl, anthracenyl, phenantrenyl, indanyl, and indenyl. In some embodiments, the aryl group has 5 to 10 carbon atoms. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl is phenyl. The term "aryl" is understood to include deuterated analogs of aryl groups as defined herein, including, but not limited to, groups such as pentadeuterated phenyl (i.e., perdeuterated phenyl, phenyl-d5) and perdeuterated naphthyl.

[0477] As used herein, “halo” refers to F, Cl, Br, or I. In some embodiments, halo is F, Cl, or Br. In some embodiments, halo is F or Cl. In some embodiments, halo is F. In some embodiments, halo is Cl.

[0478] When used herein, "C n-m A "haloalkoxy" refers to a -O-haloalkyl group having n to m carbon atoms. Exemplary haloalkoxy groups include OCF3 and OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. n~m The term “haloalkoxy” is understood to include deuterated analogs of the haloalkyl moiety of a haloalkoxy group as defined herein, including, but not limited to, groups such as deuterated difluoromethoxy (-OCDF2) and dideuterated fluoromethoxy (-OCD2F).

[0479] When used herein, "C" is used alone or in combination with other terms. n-mThe term "haloalkyl" refers to an alkyl group having 1 halogen atom ~ 2s + 1 halogen atoms (these may be the same or different), where "s" is the number of carbon atoms in the alkyl group, and the alkyl group has n ~ m carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has 1 ~ 6, 1 ~ 4, or 1 ~ 3 carbon atoms. Examples of haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCl3, CHCl2, C2Cl5, etc. n~m The term “haloalkyl” is understood to include deuterated analogs of haloalkyl groups as defined herein, including, but not limited to, groups such as deuterated difluoromethyl (-CDF2) and dideuterated fluoromethyl (-CD2F).

[0480] As used herein, the term "carbonyl," whether used alone or in combination with other terms, refers to a -C(O)- group.

[0481] When used herein, "C n-m The term "alkylcarbonyl" refers to a group of the formula -C(O)-alkyl, where the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0482] When used herein, "C n-m The term "alkylsulfonyl" refers to a group of the formula -S(O)2-alkyl, where the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0483] As used herein, the term "carboxyl" refers to the group of the formula -C(O)OH.

[0484] When used herein, "Ji (C) n-mThe term "alkyl)amino" refers to a group of the formula -N(alkyl)2, where each of the two alkyl groups independently has n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0485] As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons containing cyclized alkyl and alkenyl groups. Cycloalkyl groups may include monocyclic or polycyclic (e.g., having two fused rings) groups, spiro rings, and crosslinked rings (e.g., crosslinked bicycloalkyl groups). The ring-forming carbon atoms of cycloalkyl groups may be optionally substituted with oxo or sulfide (e.g., C(O) or C(S)). The definition of cycloalkyl also includes moieties having one or more aromatic rings fused to (i.e., sharing a bond with) a cycloalkyl ring, such as benzo or thienyl derivatives like cyclopentane and cyclohexane. Cycloalkyl groups containing fused aromatic rings may be bonded via any ring-forming atoms, including the ring-forming atoms of the fused aromatic ring. Cycloalkyl groups may have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (i.e., C 3-10 ) may have. In some embodiments, the cycloalkyl is C 3-10 It is monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is C 3-7 It is a monocyclic cycloalkyl. In some embodiments, the cycloalkyl is C 4-7 It is a monocyclic cycloalkyl. In some embodiments, the cycloalkyl is C 4-10The cycloalkyl group is a spiro ring or a crosslinked cycloalkyl group (e.g., a crosslinked bicycloalkyl group). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, kuban, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, azaspiro[2.4]heptanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. The term "cycloalkyl" is understood to include deuterated analogs of cycloalkyl groups as defined herein, including, but not limited to, perdeuterated cyclopropyl, perdeuterated cyclobutyl, perdeuterated cyclopentyl, and perdeuterated cyclohexyl.

[0486] As used herein, “heteroaryl” refers to a monocyclic or polycyclic (e.g., having two fused rings) aromatic heterocycle having at least one heteroatom ring member selected from N, O, S, and B. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, any ring-forming N in the heteroaryl portion may be an N-oxide. In some embodiments, the heteroaryl is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, the heteroaryl is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, and S. In some embodiments, the heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, the heteroaryl is a 5-6 monocyclic heteroaryl having one or two heteroatom ring members independently selected from N, O, and S. In some embodiments, the heteroaryl group contains 3-10, 4-10, 5-10, 5-7, 3-7, or 5-6 ring-forming atoms. In some embodiments, the heteroaryl group has 1-4 ring-forming heteroatoms, 1-3 ring-forming heteroatoms, 1-2 ring-forming heteroatoms, or 1 ring-forming heteroatom. If the heteroaryl group contains more than one heteroatom ring member, those heteroatoms may be the same or different.Examples of heteroaryl groups include thienyl (or thiophenyl), furyl (or furanil), pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, and 1,2-dihydro-1,2-azavolin, pyridinyl, pyrimidinyl, pyrazinyl, pyridadinyl, azolyl, triazolyl, thiadiazolyl, and quinoli. Examples include, but are not limited to, nyl, isoquinolinyl, indolyl, benzothiophenyl, benzofuranyl, benzoisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, triazinyl, thieno[3,2-b]pyridinyl, imidazo[1,2-a]pyridinyl, 1,5-naphthilidinyl, 1H-pyrazolo[4,3-b]pyridinyl, triazolo[4,3-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, indazolyl, imidazo[1,2-b]pyridadinyl, and pyrazolo[1,5-a]pyrimidinyl. The term "heteroaryl" is understood to include deuterated analogs of heteroaryl groups as defined herein, including, but not limited to, perdeuterated pyridinyl, perdeuterated pyrazinyl, and perdeuterated pyrimidinyl groups.

[0487] As used herein, "heterocycloalkyl" refers to a monocyclic or polycyclic heterocyclic ring having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl are replaced with a heteroatom selected from N, O, S, and B, and the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group may optionally be substituted with one or more oxo or sulfide groups (e.g., C(O), S(O), C(S), or S(O)2, etc.). When the ring-forming carbon atoms or heteroatoms of the heterocycloalkyl group are optionally substituted with one or more oxo or sulfide groups, the O or S of the group is added to the number of ring-forming atoms specified herein (e.g., 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl is a 6-membered heterocycloalkyl group, the ring-forming carbon atoms are substituted with an oxo group, and the 6-membered heterocycloalkyl group is further substituted with a methyl group). Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having two fused rings) systems. Heterocycloalkyl includes monocyclic and polycyclic 3- to 10-membered, 4- to 10-membered, 5- to 10-membered, 4- to 7-membered, 5- to 7-membered, or 5- to 6-membered heterocycloalkyl groups. Heterocycloalkyl groups may also include spiro and bridged rings (e.g., 5- to 10-membered bridged biheterocycloalkyl rings having one or more ring-forming carbon atoms substituted with a heteroatom independently selected from N, O, S, and B). The heterocycloalkyl group can be attached via a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. The term "heterocycloalkyl" is understood to include deuterated analogs of heterocycloalkyl groups as defined herein, including, but not limited to, groups such as perdeuterated azetidinyl, perdeuterated pyrrolidinyl, perdeuterated piperidinyl, etc.

[0488] Furthermore, the definition of heterocycloalkyl also includes moieties having one or more aromatic rings condensed (i.e., sharing a common bond) with a non-aromatic heterocyclic ring, such as piperidine, morpholine, and benzo or thienyl derivatives of azepines. Heterocycloalkyl groups containing condensed aromatic rings may be bonded via any ring-forming atoms, including the ring-forming atoms of the condensed aromatic ring. In some embodiments, heterocycloalkyl groups contain 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, heterocycloalkyl groups have 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. In some embodiments, heterocycloalkyl groups are monocyclic 4 to 6-membered heterocycloalkyl groups having 1 or 2 heteroatoms independently selected from N, O, S, and B, and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl is a monocyclic or bicyclic 5- to 10-membered heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, S, and B, and having one or more oxide ring members. In some embodiments, the heterocycloalkyl is a monocyclic or bicyclic 5- to 10-membered heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S, and having one or more oxide ring members. In some embodiments, the heterocycloalkyl is a monocyclic 5- to 6-membered heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S, and having one or more oxide ring members.

[0489] Examples of heterocycloalkyl groups include pyrrolidine-2-one (or 2-oxopyrrolidinyl), 1,3-isoxazolidine-2-one, pyranyl, tetrahydropyranyl, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, 1,2,3,4-tetrahydroisoquinoline, benzazapene, and azabishi Kuro[3.1.0]hexanil, diazabicyclo[3.1.0]hexanil, oxobicyclo[2.1.1]hexanil, azabicyclo[2.2.1]heptanil, diazabicyclo[2.2.1]heptanil, azabicyclo[3.1.1]heptanil, diazabicyclo[3.1.1]heptanil, azabicyclo[3.2.1]octanil, diazabicyclo[3.2.1]octanil, oxobicyclo[2.2.2]octanil, azaadamantanil, diazadamantanil, oxo-adamantanil, azas Pyrro[3.3]heptanil, diazaspiro[3.3]heptanil, oxo-azaspiro[3.3]heptanil, azaspiro[3.4]octanil, diazaspiro[3.4]octanil, oxo-azaspiro[3.4]octanil, azaspiro[2.5]octanil, diazaspiro[2.5]octanil, azaspiro[4.4]nonanil, diazaspiro[4.4]nonanil, oxo-azaspiro[4.4]nonanil, azaspiro[4.5]decanil, diazaspiro[4.5]decanil, diazaspiro[4.4]nonanil, oxo-diazaspiro[4.4 ]nonanil, oxo-dihydropyridazinil, oxo-2,6-diazaspiro[3.4]octanil, oxohexahydropyrrolo[1,2-a]pyradinil, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 3-oxopiperazinil, oxo-pyrrolidinil, oxo-pyridinil, 2,3-dihydrobenzo[b][1,4]dioxynil, 3,4-dihydro-2H-benzo[b][1,4]oxazinil, octahydro-2H-pyrido[1,2-a]pyradinil, 1,6-diazaspiro[3.3]heptanil, 3-azabicyclo[3.1.Examples include [0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl.

[0490] When used herein, "C o-p Cycloalkyl-C n-m "Alkyl-" refers to the group of the formula cycloalkyl-alkylene-, where the cycloalkyl group has 0 to p carbon atoms and the alkylene linking group has n to m carbon atoms.

[0491] When used herein, "C o~p Aryl-C n~m "Alkyl-" refers to the group of the formula aryl-alkylene-, where the aryl group has 0 to p carbon atoms and the alkylene linking group has n to m carbon atoms.

[0492] When used herein, "heteroaryl-C" n~m The "alkyl-" designation refers to the group of the formula heteroaryl-alkylene-, where the alkylene linking group has n to m carbon atoms.

[0493] When used herein, "heterocycloalkyl-C" n-m "Alkyl-" refers to the group of the formula heterocycloalkyl-alkylene-, and the alkylene linking group has n to m carbon atoms.

[0494] As used herein, “alkyl linking group” refers to a divalent linear or branched alkyl linking group (“alkylene group”). For example, “C o-p Cycloalkyl-C n-m Alkyl-", C o-p Aryl-C n-m Alkyl-, Phenyl-C n-m Alkyl-", "heteroaryl-C" n-m "alkyl-" and "heterocycloalkyl-C" n-mThe term "alkyl-" includes alkyl linking groups. Examples of "alkyl linking groups" or "alkylene groups" include methylene, ethane-1,1-diyl, ethane-1,2-diyl, propane-1,3-diyl, propane-1,2-diyl, and propane-1,1-diyl. The terms "alkyl linking group" and "alkylene linking group" are understood to include deuterated analogs of alkylene groups as defined herein.

[0495] In certain places, definitions or embodiments refer to specific rings (e.g., azetidine rings, pyridine rings, etc.). Unless otherwise indicated, these rings may bond to any ring member, as long as the bond does not exceed the valence of the atom in question. For example, an azetidine ring can be bonded at any position on the ring, while a pyridine-3-yl ring is bonded at position 3.

[0496] As used herein, the term "oxo" refers to an oxygen atom as a divalent substituent (i.e., =O) that, when bonded to a carbonyl group (e.g., C=O or C(O)), or when bonded to a nitrogen or sulfur heteroatom, forms a nitroso, sulfinyl, or sulfonyl group.

[0497] As used herein, the term “independently selected from” means a variable or substituent (e.g., each R). M This means that each occurrence of ) is independently selected from the applicable list for each occurrence.

[0498] The compounds described herein may be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise specified. Compounds of this disclosure containing asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. Methods for preparing optically active forms from optically inert starting materials are known in the art, such as by the separation or stereoselective synthesis of racemic mixtures. Many geometric isomers, such as olefins and C=N double bonds, may also be present in the compounds described herein, and all such stable isomers are intended in the present invention. Cis and trans geometric isomers of the compounds of this disclosure are described, and these may be isolated as mixtures of isomers or as separated isomers. In some embodiments, the compounds have an (R) configuration. In some embodiments, the compounds have an (S) configuration. Formulas provided herein (e.g., formula I, formula Ia, etc.) include stereoisomers of the compounds.

[0499] The separation of racemic mixtures of compounds can be carried out by any of the numerous methods known in the art. An exemplary method is fractional recrystallization using chiral dividing acids, which are optically active salt-forming organic acids. Suitable dividing agents for fractional recrystallization are, for example, optically active acids such as D and L-type tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, or various optically active camphorsulfonic acids such as β-camphorsulfonic acid. Other suitable dividing agents for fractional crystallization include stereoisomerically pure forms of α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, and 1,2-diaminocyclohexane.

[0500] The separation of racemic mixtures can also be carried out by elution using a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by those skilled in the art.

[0501] The compounds described herein also include tautomers. Tautomers are obtained by the exchange of adjacent double and single bonds and the simultaneous transfer of protons. Tautomers include prototropic tautomers, which are protonated states of isomers having the same empirical formula and total charge. Examples of prototropic tautomers include ketone-enol pairs, amide-imoid acid pairs, lactam-lactim pairs, enamine-imine pairs, and cyclic forms in which protons can occupy two or more positions in the heterocyclic system, such as 1H-imidazole and 3H-imidazole, 1H-1,2,4-triazole, 2H-1,2,4-triazole, and 4H-1,2,4-triazole, 1H-isoindole and 2H-isoindole, 2-hydroxypyridine and 2-pyridone, and 1H-pyrazole and 2H-pyrazole. Tautomeristic morphs may be in equilibrium or may be sterically fixed into a single morph by appropriate substitution.

[0502] All compounds and their pharmaceutically acceptable salts can be identified together with other substances such as water and solvents (e.g., hydrates and solvates) or isolated.

[0503] In some embodiments, the preparation of the compound may involve the addition of an acid or base to, for example, catalyze a desired reaction or to influence the formation of a salt form such as an acid addition salt.

[0504] In some embodiments, the compounds or salts thereof described herein are substantially isolated. "Substantially isolated" means that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation may include, for example, a composition in which the compounds described herein are concentrated. Substantial separation may include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compounds or salts thereof described herein.

[0505] The term “compound,” as used herein, means all stereoisomers, geometric isomers, tautomers, and isotopes of the illustrated structure. A compound identified herein by name or structure as a particular tautomer is intended to include other tautomers unless otherwise specified.

[0506] The term "pharmaceutically acceptable" is used herein to mean a compound, substance, composition, and / or dosage form that is suitable for use in contact with human and animal tissues within the bounds of appropriate medical judgment, and that provides a reasonable benefit-to-risk ratio without causing excessive toxicity, irritation, allergic reactions, or other problems or complications.

[0507] This application also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, “pharmaceutically acceptable salt” means a derivative of a disclosed compound in which the parent compound has been modified by converting an existing acidic or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids. pharmaceutically acceptable salts of this disclosure include, for example, conventional non-toxic salts of parent compounds formed from non-toxic inorganic or organic acids. pharmaceutically acceptable salts of this disclosure can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acidic or base form of these compounds with a stoichiometric amount of a suitable base or acid in water, an organic solvent, or a mixture thereof, generally in non-aqueous media such as ether, ethyl acetate, alcohol (e.g., methanol, ethanol, isopropanol, or butanol), or acetonitrile (ACN). A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference.

[0508] synthesis As those skilled in the art will understand, the compounds provided herein, including their salts and stereoisomers, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes, such as the synthetic routes provided in the scheme below.

[0509] The compound of formula (I) can be prepared, for example, using a process as shown in Scheme 1. In the process shown in Scheme 1, the compound of formula 1-1 (wherein L1 is a halogen (e.g., F, Cl, or Br)) is reacted with compound 1-2 by a nucleophilic aromatic substitution reaction (e.g., in the presence of a base such as N,N-diisopropylethylamine), and then the nitro group in compound 1-3 is reduced (e.g., under reducing conditions such as treatment with Zn powder, H2O, and NH4Cl) to form the compound of formula 1-4. The compound of formula 1-4 can be converted to cyclic urea 1-5 under standard conditions (e.g., in the presence of N-succinimidyl carbonate). The compound of formula 1-5 can be further converted to the compound of formula 1-6 by CN bond formation (e.g., in the presence of an alkyl halide (e.g., iodomethane) and a base (e.g., cesium carbonate)). Compounds of formulas 1-6 (wherein L2 is a halogen (e.g., Cl or Br)) are further coupled with compounds of formulas 1-7 by a Buchwald-Hartwig cross-coupling reaction (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(O), Xantphos, and cesium carbonate) to obtain compound I.

[0510] Alternatively, compounds of formula 1-8 can be prepared by using compounds of formula 1-6 and performing a Buchwald-Hartwig cross-coupling reaction (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(O), Brettphos, and cesium carbonate), followed by NH deprotection of the protecting group (e.g., treatment with HCl or TFA). Then, compounds of formula 1-8 can be coupled with compounds of formula 1-9 (wherein X is a halogen (e.g., Cl, or Br)) under a Buchwald-Hartwig cross-coupling reaction (e.g., in the presence of tris(dibenzylideneacetone)dipalladium(O), Xantphos, and cesium carbonate) to obtain compounds of formula I. [ka]

[0511] Cy 4 However, if it is a 6-membered aryl or heteroaryl ring, the compounds of formulas 1-7 and 1-9 can be prepared using a process as shown in Scheme 2. The compound of formula 2-1 (wherein X is a halogen (e.g., Cl, Br, or I)) can be reacted with compound 2-2 (where M is B(OR)2, Sn(alkyl)3, Zn-hal, etc.) under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base), or standard Still cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand) to obtain the compound of formula 2-3. After functionalization of compound 2-3 (e.g., amide coupling, cross-coupling, Grignard addition, etc.), the compounds of formulas 1-7 can be prepared.

[0512] Alternatively, the compounds of formula 2-4 (wherein X is a halogen (e.g., Cl, Br, or I)) can be converted to compound 2-5 (where M is B(OR)2, Sn(alkyl)3, etc.) under standard conditions (e.g., in the presence of a palladium catalyst and a suitable ligand). The compounds of formula 2-5 can be further converted to the compounds of formula 2-7(1-9) by a cross-coupling reaction with the compound of formula 2-6 under standard conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base). After functionalization of compound 2-7 (e.g., amide coupling, cross-coupling, Grignard addition, etc.), the compounds of formula 1-7 can be prepared.

[0513] The compounds of formulas 1-9 can also be prepared from the compounds of formulas 2-4 (wherein X is a halogen (e.g., Cl, Br, or I)) by a nucleophilic aromatic substitution reaction with compounds 2-8 (e.g., in the presence of a base such as N,N-diisopropylethylamine), followed by functional group manipulation of compound 2-9 (e.g., amide coupling, cross-coupling, Grignard addition, etc.). In scheme 2, at least one R QThe base is a variable R as defined herein. 5 In response to the additional R Q The group is H or a variable R as defined herein. 4 It corresponds to. [ka]

[0514] Cy 4 However, if the ring is 1H-pyrrolo[3,2-b]pyridine or 1H-pyrazolo[4,3-b]pyridine, compounds of formulas 1-7 and 1-9 can be prepared using a process as shown in Scheme 3. Compound 3-1 can be subjected to a halogenation reaction (e.g., in the presence of N-iodosuccinimide), followed by an alkylation reaction with compound 2-2 (where L is a halogen, OM, etc.) to obtain compound 3-3. Compound 3-3 can be reacted with compound 3-4 (e.g., where M is B(OR)2) under standard cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base) to obtain derivatives of formula 3-5. After functionalization of compound 3-5 (e.g., amide coupling, cross-coupling, Grignard addition, etc.), compounds of formulas 1-7 (where Y=NHPG) and 1-9 (where Y=halogen) can be prepared. In Scheme 3, at least one R Q The base is a variable R as defined herein. 5 In response to the additional R Q The group is H or a variable R as defined herein. 4 It corresponds to. [ka]

[0515] Cy 4However, if the ring is 3H-imidazo[4,5-b]pyridine or 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one, the compounds of formulas 1-9 can be prepared using a process as shown in Scheme 4. The compound of formula 4-1 (wherein L1 is a halogen (e.g., F, Cl, or Br)) can be reacted with compound 4-2 by a nucleophilic aromatic substitution reaction (e.g., in the presence of a base such as N,N-diisopropylethylamine) to obtain the compound of formula 4-3. The nitro group in compound 4-3 can be reduced (e.g., under reducing conditions such as treatment with Zn powder, H2O, and NH4Cl), followed by a cyclization reaction (e.g., in the presence of CDI or methyl orthoformate) to obtain the compound of formula 4-4. After functionalization of compound 4-4 (e.g., amide coupling, cross coupling, Grignard addition, etc.), the compounds of 1-9 can be prepared. In scheme 4, at least one R Q The base is a variable R as defined herein. 5 In response to the additional R Q The group is H or a variable R as defined herein. 4 It corresponds to. [ka]

[0516] Cy 4However, if it is an imidazo[1,2-b]pyridazine ring, the compounds of formulas 1-7 can be prepared using a process as shown in Scheme 5. The compound of formula 5-1 can be coupled with compound 5-2 (e.g., M is B(OR)2, Zn-hal, etc.) under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand) to produce the compound of formula 5-3. Iodination of compound 5-3 (e.g., in the presence of N-iodosuccinimide) yields the compound of formula 5-4. The compound of formula 5-4 can be reacted with compound 5-5 (e.g., M is B(OR)2) under standard cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable ligand / base) to produce the compound of formula 5-6(1-9). The compounds of formulas 5-6 can be synthesized into the compounds of formulas 1-7 by performing a Buchwald-Hartwig cross-coupling reaction (e.g., in the presence of a palladium catalyst and a suitable ligand), followed by NH deprotection of the protecting group (e.g., treatment with HCl or TFA). In scheme 5, at least one R Q The base is a variable R as defined herein. 5 In response to the additional R Q The group is H or a variable R as defined herein. 4 It corresponds to. [ka]

[0517] The reactions for preparing the compounds described herein can be carried out in suitable solvents that can be readily selected by those skilled in the art of organic synthesis. Suitable solvents may be substantially inactive with the starting materials (reactants), intermediates, or products at the temperature in which the reaction is carried out (for example, a temperature that may range from the freezing temperature to the boiling temperature of the solvent). A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the specific reaction step, a solvent suitable for that particular reaction step can be selected by those skilled in the art.

[0518] As used herein, the terms “ambient temperature,” “room temperature,” or “rt” are understood in the art and generally refer to a temperature, for example, the temperature of the room in which the reaction takes place, for example, a reaction temperature close to a temperature of about 20°C to about 30°C.

[0519] The preparation of the compounds described herein may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, as well as the selection of appropriate protecting groups, can be readily determined by those skilled in the art. For the chemical properties of protecting groups, see, for example, TW Greene and PGMWuts, Protective Groups in Organic Synthesis, 3. rd This can be found in Ed., Wiley & Sons, Inc., New York (1999).

[0520] The reaction can be monitored according to any preferred method known in the art. For example, the formation of the product can be monitored by nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C) The compounds can be monitored by spectroscopic methods such as infrared spectroscopy, spectrophotometric methods (e.g., ultraviolet-visible), mass spectrometry, or chromatographic methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin-layer chromatography (TLC). The compounds can be purified by those skilled in the art by various methods, including high-performance liquid chromatography (HPLC) and normal-phase silica chromatography.

[0521] How to use The compounds described herein may inhibit the activity of the V617F variant of the protein tyrosine kinase JAK2 (i.e., "V617F" or "JAK2V617F"). Compounds that inhibit V617F are particularly useful in providing a means to prevent tumor growth or induce apoptosis by inhibiting angiogenesis. Therefore, the compounds of this disclosure are expected to be useful in the treatment or prevention of proliferative disorders such as cancer. Tumors with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to inhibitors.

[0522] In certain embodiments, the present disclosure provides a method for treating a patient in need of treatment for a V617F-related disorder, the method comprising the step of administering to the patient a compound of the present disclosure or a pharmaceutically acceptable composition thereof.

[0523] Myeloproliferative disorders (MPDs) are pluripotent hematopoietic stem cell disorders characterized by the overproduction of various blood cells. MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF). JAK2 V617F mutations have been reported in approximately 95% of patients with PV, 35%–70% of patients with ET, and 50% of patients with IMF. In addition, JAK2 exon 12 mutations have been detected in some V617F-negative PV patients (Ma et al., J.Mol.Diagn., 11:49-53, 2009). In some embodiments, the compounds of the present disclosure may be useful in treating patients who require treatment for myeloproliferative disorders (e.g., myeloproliferative neoplasms), such as polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), eosinophilic syndrome (HES), and systemic mastocytosis (SMCD).

[0524] In some embodiments, the myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, primary myelofibrosis, myelofibrosis that has progressed from essential thrombocythemia, and myelofibrosis that has progressed from polycythemia vera.

[0525] In some embodiments, the myeloproliferative disorder is a myeloproliferative neoplasm.

[0526] In some embodiments, the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or myelofibrosis that has progressed from polycythemia vera / essential thrombocythemia (Post-PV / ET MF)).

[0527] In some embodiments, the myeloproliferative disorder is primary myelofibrosis (PMF).

[0528] In some embodiments, the myeloproliferative disorder is post-essential thrombocythemia myelofibrosis (Post-ET MF).

[0529] In some embodiments, the myeloproliferative disorder is post-polycythemia vera myelofibrosis (Post-PV MF).

[0530] In some embodiments, the myeloproliferative disorder is selected from primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET).

[0531] In some embodiments, the myeloproliferative neoplasm is primary myelofibrosis (PMF).

[0532] In some embodiments, the myeloproliferative neoplasm is polycythemia vera (PV).

[0533] In some embodiments, the myeloproliferative neoplasm is essential thrombocythemia (ET).

[0534] Myeloproliferative disorders include disorders of cell types originating from the bone marrow or lymph nodes, such as white blood cells. Myeloproliferative disorders can manifest as abnormal cell division resulting in abnormal levels of specific blood cell populations. The abnormal cell division underlying myeloproliferative blood disorders is typically cell-specific and not a normal physiological response to infection or inflammation. Leukemia is a type of myeloproliferative disorder. Exemplary myeloproliferative disorders include, but are not limited to, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), hairy cell leukemia, leukemic manifestation of lymphoma, multiple myeloma, polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF), eosinophilic syndrome (HES), chronic neutrophilic leukemia (CNL), myelofibrosis with myelometaplasia (MMM), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis (SM), and unclassified myeloproliferative disorders (UMPD or MPD-NC). Lymphoma is a type of proliferative disorder that primarily affects lymphoid organs such as lymph nodes, the liver, and the spleen. Exemplary proliferative lymphoid disorders include lymphocytic lymphoma (also known as chronic lymphocytic leukemia), follicular lymphoma, large cell lymphoma, Burkitt lymphoma, marginal zone lymphoma, and lymphoblastic lymphoma (also known as acute lymphoblastic lymphoma).

[0535] For example, the compounds of this disclosure are useful in the treatment of cancer. Typical cancers include bladder cancer (e.g., urothelial carcinoma, squamous cell carcinoma, adenocarcinoma), breast cancer (e.g., hormone receptor R-positive, triple-negative), cervical cancer, colorectal cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, gastric cancer (e.g., gastrointestinal stromal tumor), head and neck cancer (e.g., laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, lip cancer, head and neck squamous cell carcinoma), kidney cancer (e.g., renal cell carcinoma, urothelial carcinoma, sarcoma, Wilms' tumor), liver cancer (e.g., hepatocellular carcinoma, cholangiocarcinoma (e.g., intrahepatic, hilar, or peripulmonary, distal extrahepatic), hepatic angiosarcoma, hepatocyte Examples include tumors, lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung cancer, small cell and non-small cell carcinoma, bronchial cancer, bronchial adenoma, pleuroblastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, gallbladder cancer, pancreatic cancer (e.g., exocrine splenic cancer), stomach cancer, thyroid cancer, parathyroid cancer, neurosecretory cancer (e.g., pheochromocytoma, Merkel cell carcinoma, neurosecretory carcinoma), skin cancer (e.g., squamous cell carcinoma, Kaposi's sarcoma, Merkel cell carcinoma), and brain cancer (e.g., astrocytoma, medulloblastoma, ependymoma, neuroexocrine tumor, pineal gland tumor).

[0536] Further exemplary cancers include hematopoietic malignancies, such as leukemia or lymphoma, including multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, acute myeloid leukemia (AML), B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin lymphoma, myeloproliferative neoplasms (e.g., 8p11 myeloproliferative syndrome, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)), myelodysplastic syndromes, chronic eosinophilic leukemia, Waldenström macroglobulinemia, hairy cell lymphoma, chronic myeloid lymphoma, acute lymphoblastic lymphoma, AIDS-associated lymphoma, and Burkitt lymphoma.

[0537] In certain embodiments, a method for treating cancer is provided herein, the method comprising administering a therapeutically effective amount of the compound of the present disclosure to a patient in need thereof. In certain embodiments, the cancer is selected from T lymphoblastic lymphoma, glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma, and osteosarcoma.

[0538] Other cancers treatable with the compounds of this disclosure include tumors of the eye, glioblastoma, melanoma, leiomyosarcoma, and urothelial carcinoma (e.g., ureter, urethra, bladder, urachus).

[0539] The compounds disclosed herein may also be useful in inhibiting tumor metastasis.

[0540] In some embodiments, the compounds of this disclosure described herein can be used to treat Alzheimer's disease, HIV, or tuberculosis.

[0541] In some embodiments, the compounds of the present disclosure may be useful in treating myelodysplastic syndrome (MDS) in patients who require treatment for it. In some embodiments, the patients with myelodysplastic syndrome (MDS) are red blood cell transfusion dependent.

[0542] As used herein, myelodysplastic syndromes are intended to encompass xenophobic and clonal hematopoietic disorders characterized by ineffective hematopoiesis in one or more of the major myeloid cell lineages. Myelodysplastic syndromes are associated with bone marrow failure, peripheral cytopenia, and a tendency to progress to acute myeloid leukemia (AML). Furthermore, clonal cytogenetic abnormalities can be detected in approximately 50% of cases of MDS. In 1997, the World Health Organization (WHO), together with the Society for Hematopathology (SH) and the European Association of Hematopathology (EAHP), proposed a new classification of hematopoietic malignancies (Harris, et al., J Clin Oncol 1999;17:3835-3849, Vardiman, et al., Blood 2002;100:2292-2302). In the case of MDS, the WHO not only utilized morphological criteria from the French-American-British (FAB) classification but also incorporated genetic, biological, and clinical features available to define subsets of MDS (Bennett, et al., Br.J.Haematol. 1982;51:189-199). In 2008, the WHO classification of MDS (Table 1) was further improved to allow for accurate and prognostically relevant subclassifications of monocytic lineage dysplasia by incorporating new clinical and scientific information (Vardiman, et al., Blood 2009;114:937-951; Swerdlow, et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon France: IARC Press; 2008:88-103; Bunning and Germing, “Myelodysplastic syndromes / neoplasms” in Chapter 5; Swerdlow, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (ed. 4th edition): Lyon, France: IARC Press; 2008:88-103). [Table 1]

[0543] In some embodiments, myelodysplastic syndrome is a refractory cytopenia (RCUD) with dysplasia of a single blood cell lineage.

[0544] In some embodiments, myelodysplastic syndrome is refractory anemia with ring sideroblasts (RARS).

[0545] In some embodiments, myelodysplastic syndrome is refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).

[0546] In some embodiments, myelodysplastic syndrome is a refractory cytopenia with dysplasia of polycytic lineages.

[0547] In some embodiments, myelodysplastic syndrome is refractory anemia-1 (RAEB-1) with blast cell proliferation.

[0548] In some embodiments, myelodysplastic syndrome is refractory anemia-2 (RAEB-2) with blast cell proliferation.

[0549] In some embodiments, myelodysplastic syndrome is myelodysplastic syndrome unclassified (MDS-U).

[0550] In some embodiments, myelodysplastic syndrome is a myelodysplastic syndrome associated with the isolated del(5q).

[0551] In some embodiments, myelodysplastic syndromes are refractory to erythropoiesis-stimulating agents.

[0552] In some embodiments, the compounds of the present disclosure may be useful in the treatment of myeloproliferative disorders / myelodysplastic overlap syndromes (MPD / MDS overlap syndromes).

[0553] In some embodiments, the compounds of the present disclosure may be useful in the treatment of leukemia.

[0554] In some embodiments, the compounds of the present disclosure may be useful in the treatment of acute myeloid leukemia (AML).

[0555] In addition to carcinogenic tumors, the compounds of this disclosure may be useful in the treatment of skeletal and chondrocyte disorders, including, but not limited to, achondroplasia, hypochondroplasia, dwarfism, fatal dysplasia of bone (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Behle-Stevenson gyroscal syndrome, Pfeiffer syndrome, and craniosynostosis.

[0556] The compounds provided herein may be even more useful in the treatment of fibrotic diseases, such as when the disease symptoms or disorders are characterized by fibrosis. Examples of fibrotic diseases include cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing.

[0557] In some embodiments, the compounds provided herein can be used to treat hypophosphatemic disorders such as X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced osteomalacia.

[0558] In some embodiments, what is provided herein is a method for increasing a patient's survival or progression-free survival, comprising administering a compound provided herein to the patient. In some embodiments, the patient has cancer. In some embodiments, the patient has a disease or disorder described herein. Where used herein, progression-free survival refers to the length of time during and after treatment of a solid tumor in which a patient lives with the disease but does not worsen. Progression-free survival refers to the period from the first administration of the compound to death or disease progression, whichever comes first. Disease progression can be defined by RECIST v.1.1 (Solid Tumor Response Assessment Criteria) as evaluated by an independent Central Institutional Review Board. In some embodiments, administration of the compound results in progression-free survival of about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, about 12 months, about 16 months, or about 24 months or more. In some embodiments, administration of the compound results in a progression-free survival of at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, or about 12 months; and less than 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months, or about 2 months. In some embodiments, administration of the compound results in an increase in progression-free survival of at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 9 months, or about 12 months; and less than 24 months, about 16 months, about 12 months, about 9 months, about 8 months, about 6 months, about 5 months, about 4 months, about 3 months, or about 2 months.

[0559] This disclosure further provides the compounds described herein, or pharmaceutically acceptable salts thereof, for use in any of the methods described herein.

[0560] This disclosure further provides the use of the compounds described herein, or pharmaceutically acceptable salts thereof, for preparing pharmaceuticals for use in any of the methods described herein.

[0561] As used herein, the term “cell” means in vitro, ex vivo, or in vivo cells. In some embodiments, ex vivo cells may be part of a tissue sample excised from an organism such as a mammal. In some embodiments, in vitro cells may be cells in a cell culture. In some embodiments, in vivo cells are cells residing within an organism such as a mammal.

[0562] As used herein, the term “contact” refers to integrating the parts shown in an in vitro or in vivo system. For example, “contact” the V617F variant with the compound described herein includes, in addition to administering the compound described herein to an individual or patient, such as a human, having the V617F variant, introducing the compound described herein into a sample containing a cell preparation or purified preparation containing the V617F variant.

[0563] As used herein, the interchangeable terms “individual” or “patient” refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates, most preferably humans.

[0564] As used herein, the term “therapeutic effective dose” refers to an amount of an active compound or pharmaceutical agent, such as any amount of any of the solid forms or salts thereof disclosed herein, that elicits a biological or pharmacokinetic response in a tissue, system, animal, individual, or human, as sought by a researcher, veterinarian, physician, or other clinician. The appropriate “effective” dose in any individual case can be determined using techniques known to those skilled in the art.

[0565] The term "pharmaceutically acceptable" is used herein to mean a compound, substance, composition, and / or dosage form that is suitable for use in contact with human and animal tissues within the bounds of appropriate medical judgment, and that provides a reasonable benefit / risk ratio without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications.

[0566] As used herein, the term “pharmaceutically acceptable carrier or excipient” refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating agent. Excipients or carriers are generally safe and non-toxic, not biologically or otherwise undesirable, and include excipients or carriers that are acceptable for veterinary and human pharmaceutical applications. In one embodiment, each component is “pharmaceutically acceptable...

Claims

1. Compound of formula I, 【Chemistry 1】 or a pharmaceutically acceptable salt thereof, in the formula: R １ is C １～６ alkyl, C ２～６ alkenyl, and C ２～６ alkynyl, and the C １ of said R １～６ alkyl, C ２～６ alkenyl, and C ２～６ alkynyl are each optionally substituted with one, two, or three independently selected R １Ａ substituents, Each R １Ａ is halo, oxo, CN, NO ２ OR ａ１１ SR ａ１１ NHOR ａ１１ C(O)R ｂ１１ C(O)NR ｃ１１ R ｄ１１ C(O)NR ｃ１１ (OR ａ１１ ), C(O)OR ａ１１ OC(O)R ｂ１１ OC(O)NR ｃ１１ R ｄ１１ NR ｃ１１ R ｄ１１ NR ｃ１１ NR ｃ１１ R ｄ１１ NR ｃ１１ C(O)R ｂ１１ NR ｃ１１ C(O)OR ａ１１ NR ｃ１１ C(O)NR ｃ１１ R ｄ１１ C(=NR ｅ１１ )R ｂ１１ C(=NR ｅ１１ )NR ｃ１１ R ｄ１１ NR ｃ１１ C(=NR ｅ１１ )NR ｃ１１ R ｄ１１ NR ｃ１１ C(=NR ｅ１１ )R ｂ１１ NR ｃ１１ S(O)R ｂ１１ NR ｃ１１ S(O)NR ｃ１１ R ｄ１１ NR ｃ１１ S(O) ２ R ｂ１１ NR ｃ１１ S(O)(=NR ｅ１１ )R ｂ１１ NR ｃ１１ S(O) ２ NR ｃ１１ R ｄ１１ S(O)R ｂ１１ S(O)NR ｃ１１ R ｄ１１ S(O) ２ R ｂ１１ S(O) ２ NR ｃ１１ R ｄ１１ , OS(O)(=NR ｅ１１ ) R ｂ１１ , and OS(O) ２ R ｂ１１ Selected independently from, Each R ａ１１ , R ｂ１１ , R ｃ１１ , and R ｄ１１ is independently selected from H, C １～６ alkyl, C １～６ haloalkyl, C ２～６ alkenyl, and C ２～６ alkynyl, and said R ａ１１ , R ｂ１１ , R ｃ１１ and R ｄ１１ of C １～６ alkyl, C ２～６ alkenyl, and C ２～６ alkynyl are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R Ｍ substituents, Each R ｅ１１ is independently selected from H, OH, CN, C １～６ alkyl, C １～６ alkoxy, C １～６ haloalkyl, C １～６ haloalkoxy, C ２～６ alkenyl, and C ２～６ alkynyl, Cy ２ However, C ３～１０ Selected from cycloalkyl and 4- to 12-membered heterocycloalkyl, the C ３～１０ Each of the cycloalkyl and 4- to 12-membered heterocycloalkyl groups consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２ Substituting with substituents, Each R ２ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl-, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ２ , SR ａ２ , NHOR ａ２ , C(O)R ｂ２ C(O)NR ｃ２ R ｄ２ C(O)NR ｃ２ (OR ａ２ ), C(O)OR ａ２ OC(O)R ｂ２ , OC(O)NR ｃ２ R ｄ２ , NR ｃ２ R ｄ２ , NR ｃ２ NR ｃ２ R ｄ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , NR ｃ２ C(O)NR ｃ２ R ｄ２ , C(=NR ｅ２ ) R ｂ２ , C(=NR ｅ２ ) NR ｃ２ R ｄ２ , NR ｃ２ C (=NR ｅ２ ) NR ｃ２ R ｄ２ , NR ｃ２ C (=NR ｅ２ ) R ｂ２ , NR ｃ２ S(O)R ｂ２ , NR ｃ２ S(O)NR ｃ２ R ｄ２ , NR ｃ２ S(O) ２ R ｂ２ , NR ｃ２ S(O)(=NR ｅ２ ) R ｂ２ , NR ｃ２ S(O) ２ NR ｃ２ R ｄ２ S(O)R ｂ２ S(O)NR ｃ２ R ｄ２ , S(O) ２ R ｂ２ , S(O) ２ NR ｃ２ R ｄ２ , OS(O)(=NR ｅ２ ) R ｂ２ OS(O) ２ R ｂ２ SF ５ P(O)R ｆ２ R ｇ２ , OP(O)(OR ｈ２ ) ( OR ｉ２ ), P(O)(OR ｈ２ ) ( OR ｉ２ ), and BR ｊ２ R ｋ２ Selected independently from, the R ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ａ Optionally substituted with substituents, Each R ａ２ , R ｃ２ , and R ｄ２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ２ , R ｃ２ and R ｄ２ C １～６ Alkyl, Ｃ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ａ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ２ and R ｄ２ However, together with the N atom to which they are bonded, they form a 5-10 member heteroaryl or 4-10 member heterocycloalkyl group, and the 5-10 member heteroaryl or 4-10 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. ２Ａ Optionally substituted with substituents, Each R ｂ２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ａ Optionally substituted with substituents, Each R ｅ２ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｆ２ and R ｇ２ However, H, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｈ２ and R ｉ２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｊ２ and R ｋ２ However, OH, C １～６ Alkoxy, and C １～６ Selected independently from haloalkoxys, or any R bonded to the same B atom ｊ２ and R ｋ２ However, along with the aforementioned B atoms to which they are bonded, C １～６ Alkyl and C １～６ A 5- or 6-membered heterocycloalkyl group is formed, which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the haloalkyl group. Each R ２Ａ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl-, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ２１ , SR ａ２１ , NHOR ａ２１ , C(O)R ｂ２１ C(O)NR ｃ２１ R ｄ２１ C(O)NR ｃ２１ (OR ａ２１ ), C(O)OR ａ２１ OC(O)R ｂ２１ , OC(O)NR ｃ２１ R ｄ２１ , NR ｃ２１ R ｄ２１ , NR ｃ２１ NR ｃ２１ R ｄ２１ , NR ｃ２１ C(O)R ｂ２１ , NR ｃ２１ C(O)OR ａ２１ , NR ｃ２１ C(O)NR ｃ２１ R ｄ２１ , C(=NR ｅ２１ ) R ｂ２１ , C(=NR ｅ２１ ) NR ｃ２１ R ｄ２１ , NR ｃ２１ C (=NR ｅ２１ ) NR ｃ２１ R ｄ２１ , NR ｃ２１ C (=NR ｅ２１ ) R ｂ２１ , NR ｃ２１ S(O)R ｂ２１ , NR ｃ２１ S(O)NR ｃ２１ R ｄ２１ , NR ｃ２１ S(O) ２ R ｂ２１ , NR ｃ２１ S(O)(=NR ｅ２１ ) R ｂ２１ , NR ｃ２１ S(O) ２ NR ｃ２１ R ｄ２１ S(O)R ｂ２１ S(O)NR ｃ２１ R ｄ２１ , S(O) ２ R ｂ２１ , S(O) ２ NR ｃ２１ R ｄ２１ , OS(O)(=NR ｅ２１ ) R ｂ２１ OS(O) ２ R ｂ２１ SF ５ P(O)R ｆ２１ R ｇ２１ , OP(O)(OR ｈ２１ ) ( OR ｉ２１ ), P(O)(OR ｈ２１ ) ( OR ｉ２１ ), and BR ｊ２１ R ｋ２１ Selected independently from, the R ２Ａ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ｂ Optionally substituted with substituents, Each R ａ２１ , R ｃ２１ , and R ｄ２１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ２１ , R ｃ２１ and R ｄ２１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ｂ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ２１ and R ｄ２１ However, together with the N atom to which they are bonded, they form a 5-10 member heteroaryl or 4-10 member heterocycloalkyl group, and the 5-10 member heteroaryl or 4-10 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. ２Ｂ Optionally substituted with substituents, Each R ｂ２１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ２１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ２Ｂ Optionally substituted with substituents, Each R ｅ２１ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｆ２１ and R ｇ２１ However, H, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｈ２１ and R ｉ２１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｊ２１ and R ｋ２１ However, OH, C １～６ Alkoxy, and C １～６ Selected independently from haloalkoxys, or any R bonded to the same B atom ｊ２１ and R ｋ２１ However, along with the aforementioned B atoms to which they are bonded, C １～６ Alkyl and C １～６ A 5- or 6-membered heterocycloalkyl group is formed, which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the haloalkyl group. Each R ２Ｂ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl-, (4-7 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ２２ , SR ａ２２ , NHOR ａ２２ , C(O)R ｂ２２ C(O)NR ｃ２２ R ｄ２２ C(O)NR ｃ２２ (OR ａ２２ ), C(O)OR ａ２２ OC(O)R ｂ２２ , OC(O)NR ｃ２２ R ｄ２２ , NR ｃ２２ R ｄ２２ , NR ｃ２２ NR ｃ２２ R ｄ２２ , NR ｃ２２ C(O)R ｂ２２ , NR ｃ２２ C(O)OR ａ２２ , NR ｃ２２ C(O)NR ｃ２２ R ｄ２２ , C(=NR ｅ２２ ) R ｂ２２ , C(=NR ｅ２２ ) NR ｃ２２ R ｄ２２ , NR ｃ２２ C (=NR ｅ２２ ) NR ｃ２２ R ｄ２２ , NR ｃ２２ C (=NR ｅ２２ ) R ｂ２２ , NR ｃ２２ S(O)R ｂ２２ , NR ｃ２２ S(O)NR ｃ２２ R ｄ２２ , NR ｃ２２ S(O) ２ R ｂ２２ , NR ｃ２２ S(O)(=NR ｅ２２ ) R ｂ２２ , NR ｃ２２ S(O) ２ NR ｃ２２ R ｄ２２ S(O)R ｂ２２ S(O)NR ｃ２２ R ｄ２２ , S(O) ２ R ｂ２２ , S(O) ２ NR ｃ２２ R ｄ２２ , OS(O)(=NR ｅ２２ ) R ｂ２２ , and OS(O) ２ R ｂ２２ Selected independently from, the R ２Ｃ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl-, (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ａ２２ , R ｃ２２ , and R ｄ２２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ２２ , R ｃ２２ and R ｄ２２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ２２ and R ｄ２２ However, together with the N atom to which they are bonded, they form a 5-6 member heteroaryl or 4-7 member heterocycloalkyl group, and the 5-6 member heteroaryl or 4-7 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. Ｍ Optionally substituted with substituents, Each R ｂ２２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ２２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ｅ２２ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, R ３ However, H, Haro, C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Selected from Alkinir, Cy ４ However, C ６～１０ Selected from aryls and 5-14 member heteroaryls, the C ６～１０ Each of the aryl and 5- to 12-membered heteroaryls has 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ４ Optionally substituted with substituents, Each R ４ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl-, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ４ , SR ａ４ , NHOR ａ４ , C(O)R ｂ４ C(O)NR ｃ４ R ｄ４ C(O)NR ｃ４ (OR ａ４ ), C(O)OR ａ４ OC(O)R ｂ４ , OC(O)NR ｃ４ R ｄ４ , NR ｃ４ R ｄ４ , NR ｃ４ NR ｃ４ R ｄ４ , NR ｃ４ C(O)R ｂ４ , NR ｃ４ C(O)OR ａ４ , NR ｃ４ C(O)NR ｃ４ R ｄ４ , C(=NR ｅ４ ) R ｂ４ , C(=NR ｅ４ ) NR ｃ４ R ｄ４ , NR ｃ４ C (=NR ｅ４ ) NR ｃ４ R ｄ４ , NR ｃ４ C (=NR ｅ４ ) R ｂ４ , NR ｃ４ S(O)R ｂ４ , NR ｃ４ S(O)NR ｃ４ R ｄ４ , NR ｃ４ S(O) ２ R ｂ４ , NR ｃ４ S(O)(=NR ｅ４ ) R ｂ４ , NR ｃ４ S(O) ２ NR ｃ４ R ｄ４ S(O)R ｂ４ S(O)NR ｃ４ R ｄ４ , S(O) ２ R ｂ４ , S(O) ２ NR ｃ４ R ｄ４ , OS(O)(=NR ｅ４ ) R ｂ４ OS(O) ２ R ｂ４ SF ５ P(O)R ｆ４ R ｇ４ , OP(O)(OR ｈ４ ) ( OR ｉ４ ), P(O)(OR ｈ４ ) ( OR ｉ４ ), and BR ｊ４ R ｋ４ Selected independently from, the R ４ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ａ４ , R ｃ４ , and R ｄ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ４ , R ｃ４ and R ｄ４ C １～６ Alkyl, Ｃ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ４Ａ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ４ and R ｄ４ However, together with the N atom to which they are bonded, they form a 5-10 member heteroaryl or 4-10 member heterocycloalkyl group, and the 5-10 member heteroaryl or 4-10 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. ４Ａ Optionally substituted with substituents, Each R ｂ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ４ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ｅ４ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｆ４ and R ｇ４ However, H, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｈ４ and R ｉ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl groups, Each R ｊ４ and R ｋ４ However, OH, C １～６ Alkoxy, and C １～６ Selected independently from haloalkoxys, or any R bonded to the same B atom ｊ４ and R ｋ４ However, along with the aforementioned B atoms to which they are bonded, C １～６ Alkyl and C １～６ A 5- or 6-membered heterocycloalkyl group is formed, which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the haloalkyl group. Each R ４Ａ is halo, oxo, C １～６ alkyl, C １～６ haloalkyl, C ２～６ alkenyl, C ２～６ alkynyl, C ６～１０ aryl, C ３～１０ cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, C ６～１０ aryl-C １～６ alkyl-, C ３～１０ cycloalkyl-C １～６ alkyl-, (5- to 10-membered heteroaryl)-C １～６ alkyl-, (4- to 10-membered heterocycloalkyl)-C １～６ alkyl-, CN, NO ２ , OR ａ４１ , SR ａ４１ , NHOR ａ４１ , C(O)R ｂ４１ , C(O)NR ｃ４１ R ｄ４１ , C(O)NR ｃ４１ (OR ａ４１ ), C(O)OR ａ４１ , OC(O)R ｂ４１ , OC(O)NR ｃ４１ R ｄ４１ , NR ｃ４１ R ｄ４１ , NR ｃ４１ NR ｃ４１ R ｄ４１ , NR ｃ４１ C(O)R ｂ４１ , NR ｃ４１ C(O)OR ａ４１ , NR ｃ４１ C(O)NR ｃ４１ R ｄ４１ , C(=NR ｅ４１ )R ｂ４１ , C(=NR ｅ４１ )NR ｃ４１ R ｄ４１ , NR ｃ４１ C(=NR ｅ４１ )NR ｃ４１ R ｄ４１ , NR ｃ４１ C(=NR ｅ４１ )R ｂ４１ , NR ｃ４１ S(O)R ｂ４１ , NR ｃ４１ SONR ｃ４１ R ｄ４１ 、NR ｃ４１ S(O) ２ R ｂ４１ 、NR ｃ４１ S(O)(=NR ｅ４１ )R ｂ４１ 、NR ｃ４１ S(O) ２ NR ｃ４１ R ｄ４１ 、S(O)R ｂ４１ 、S(O)NR ｃ４１ R ｄ４１ 、S(O) ２ R ｂ４１ 、S(O) ２ NR ｃ４１ R ｄ４１ 、OS(O)(=NR ｅ４１ )R ｂ４１ 、OS(O) ２ R ｂ４１ 、SF ５ 、P(O)R ｆ４１ R ｇ４１ 、OP(O)(OR ｈ４１ )(OR ｉ４１ )、P(O)(OR ｈ４１ )(OR ｉ４１ )、及びBR ｊ４１ R ｋ４１ から独立して選択され、前記R ４１ のC １～６ アルキル、C ２～６ アルケニル、C ２～６ アルキニル、C ６～１０ アリール、C ３～１０ シクロアルキル、5~10員ヘテロアリール、4~10員ヘテロシクロアルキル、C ６～１０ アリール-C １～６ アルキル-、C ３～１０ シクロアルキル-C １～６ アルキル-、(5~10員ヘテロアリール)-C １～６ アルキル-、及び(4~10員ヘテロシクロアルキル)-C １～６ アルキル-は各々、1、2、3、4、5、6、7、または8個の独立して選択されるR ４Ｂ 置換基で任意に置換され、 Each R ａ４１ , R ｃ４１ , and R ｄ４１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, Ｃ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ４１ , R ｃ４１ and R ｄ４１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ４Ｂ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ４１ and R ｄ４１ However, together with the N atom to which they are bonded, they form a 5-10 member heteroaryl or 4-10 member heterocycloalkyl group, and the 5-10 member heteroaryl or 4-10 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. ４Ｂ Optionally substituted with substituents, Each R ｂ４１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ４１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ４Ｂ Optionally substituted with substituents, Each R ｅ４１ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｆ４１ and R ｇ４１ However, H, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｈ４１ and R ｉ４１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｊ４１ and R ｋ４１ However, OH, C １～６ Alkoxy and C １～６ Selected independently from haloalkoxys, or any R bonded to the same B atom ｊ４１ and R ｋ４１ However, along with the aforementioned B atoms to which they are bonded, C １～６ Alkyl and C １～６ A 5- or 6-membered heterocycloalkyl group is formed, which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the haloalkyl group. Each R ４Ｂ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl-, (4-7 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ４２ , SR ａ４２ , NHOR ａ４２ , C(O)R ｂ４２ , C(O)NR ｃ４２ R ｄ４２ , C(O)NR ｃ４２ (OR ａ４２ ), C(O)OR ａ４２ OC(O)R ｂ４２ , OC(O)NR ｃ４２ R ｄ４２ , NR ｃ４２ R ｄ４２ , NR ｃ４２ NR ｃ４２ R ｄ４２ , NR ｃ４２ C(O)R ｂ４２ , NR ｃ４２ C(O)OR ａ４２ , NR ｃ４２ C(O)NR ｃ４２ R ｄ４２ , C(=NR ｅ４２ ) R ｂ４２ , C(=NR ｅ４２ ) NR ｃ４２ R ｄ４２ , NR ｃ４２ C (=NR ｅ４２ ) NR ｃ４２ R ｄ４２ , NR ｃ４２ C (=NR ｅ４２ ) R ｂ４２ , NR ｃ４２ S(O)R ｂ４２ , NR ｃ４２ S(O)NR ｃ４２ R ｄ４２ , NR ｃ４２ S(O) ２ R ｂ４２ , NR ｃ４２ S(O)(=NR ｅ４２ ) R ｂ４２ , NR ｃ４２ S(O) ２ NR ｃ４２ R ｄ４２ S(O)R ｂ４２ S(O)NR ｃ４２ R ｄ４２ , S(O) ２ R ｂ４２ , S(O) ２ NR ｃ４２ R ｄ４２ , OS(O)(=NR ｅ４２ ) R ｂ４２ , and OS(O) ２ R ｂ４２ Selected independently from, the R ４Ｃ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ａ４２ , R ｃ４２ , and R ｄ４２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ４２ , R ｃ４２ and R ｄ４２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ４２ and R ｄ４２ However, together with the N atom to which they are bonded, they form a 5-6 member heteroaryl or 4-7 member heterocycloalkyl group, and the 5-6 member heteroaryl or 4-7 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. Ｍ Optionally substituted with substituents, Each R ｂ４２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ４２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ｅ４２ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently of alkyl, R ５ However, C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～１２ Cycloalkyl, C ６～１０ Aryl, 5-12 member heteroaryl, 4-12 member heterocycloalkyl, OR ｗ２ , SR ｗ２ , NR ｗ２ R ｗ３ , C(O)R ｗ２ , C(O)NR ｗ２ R ｗ３ , C(O)OR ｗ２ OC(O)R ｗ２ , OC (NR ｗ３ ) R ｗ２ , OC(O)NR ｗ２ R ｗ３ , NR ｗ３ C(O)R ｗ２ , NR ｗ３ C(O)OR ｗ２ , NR ｗ３ C(O)NR ｗ２ R ｗ３ , NR ｗ３ S(O)R ｗ２ , NR ｗ３ S(O)NR ｗ２ R ｗ３ , NR ｗ３ S(O) ２ R ｗ２ S(O)R ｗ２ S(O)NR ｗ２ R ｗ３ , S(O) ２ R ｗ２ , and S(O) ２ NR ｗ２ R ｗ３ Selected from, The aforementioned R ５ C １～６ Alkyl and C ６～１０ Each aryl has one R ｗ１ The substituent and one, two, three, four, five, six, seven, or eight independently selected R atoms that can be optionally substituted. ５Ａ Substituting with a substituent, or The aforementioned R ５ C ６～１０ Aaryl is one R ｗ５ The substituent and one, two, three, four, five, six, seven, or eight independently selected R atoms that can be optionally substituted. ５Ａ Substituting with substituents, The aforementioned R ５ C ２～６ Alkenil, C ２～６ Alkinyl, C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl each have 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ５Ａ Optionally substituted with substituents, R ｗ１ However, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, C ６～１２ Aryl, 4-12 member heterocycloalkyl, OR ｗ４ NHR ｗ４ , NR ｗ３ R ｗ４ , SR ｗ４ , S(O) ２ R ｗ４ , C(O)R ｗ４ , C(O)NHR ｗ４ , C(O)NR ｗ３ R ｗ４ OC(O)R ｗ４ S(O)R ｗ３ S(O)NR ｗ３ R ｗ３ , S(O) ２ R ｗ２ , and S(O) ２ NR ｗ３ R ｗ３ Selected from, the R ｗ１ C ２～６ Alkenil, C ２～６ Alkinyl, C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, C ６～１２ Each of the aryl and 4- to 12-membered heterocycloalkyl groups is independently selected from 1, 2, 3, 4, 5, 6, 7, or 8 R groups. ５Ａ Optionally substituted with substituents, Each R ｗ２ However, C ３～１２ A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, and the R ｗ２ C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl each have 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ５Ａ Optionally substituted with substituents, Each R ｗ３ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｗ３ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ａ Optionally substituted with substituents, Each R ｗ４ However, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ５１ , R ｃ５１ and R ｄ５１ C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ｂ Optionally substituted with substituents, R ｗ５ However, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl-, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ５１ , SR ａ５１ , NHOR ａ５１ , C(O)R ｂ５１ , C(O)NR ｃ５１ R ｄ５１ , C(O)NR ｃ５１ (OR ａ５１ ), C(O)OR ａ５１ OC(O)R ｂ５１ , OC(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ R ｄ５１ , NR ｃ５１ NR ｃ５１ R ｄ５１ , NR ｃ５１ C(O)R ｂ５１ , NR ｃ５１ C(O)OR ａ５１ , NR ｃ５１ C(O)NR ｃ５１ R ｄ５１ , C(=NR ｅ５１ ) R ｂ５１ , C(=NR ｅ５１ ) NR ｃ５１ R ｄ５１ , NR ｃ５１ C (=NR ｅ５１ ) NR ｃ５１ R ｄ５１ , NR ｃ５１ C (=NR ｅ５１ ) R ｂ５１ , NR ｃ５１ S(O)R ｂ５１ , NR ｃ５１ S(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ S(O) ２ R ｂ５１ , NR ｃ５１ S(O)(=NR ｅ５１ ) R ｂ５１ , NR ｃ５１ S(O) ２ NR ｃ５１ R ｄ５１ S(O)R ｂ５１ S(O)NR ｃ５１ R ｄ５１ , S(O) ２ R ｂ５１ , S(O) ２ NR ｃ５１ R ｄ５１ , OS(O)(=NR ｅ５１ ) R ｂ５１ OS(O) ２ R ｂ５１ SF ５ P(O)R ｆ５１ R ｇ５１ , OP(O)(OR ｈ５１ ) ( OR ｉ５１ ), P(O)(OR ｈ５１ ) ( OR ｉ５１ ), or BR ｊ５１ R ｋ５１ C is replaced by １～６ Alkyl, and R ｗ５ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ｂ Optionally substituted with substituents, Each R ５Ａ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl-, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ５１ , SR ａ５１ , NHOR ａ５１ , C(O)R ｂ５１ , C(O)NR ｃ５１ R ｄ５１ , C(O)NR ｃ５１ (OR ａ５１ ), C(O)OR ａ５１ OC(O)R ｂ５１ , OC(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ R ｄ５１ , NR ｃ５１ NR ｃ５１ R ｄ５１ , NR ｃ５１ C(O)R ｂ５１ , NR ｃ５１ C(O)OR ａ５１ , NR ｃ５１ C(O)NR ｃ５１ R ｄ５１ , C(=NR ｅ５１ ) R ｂ５１ , C(=NR ｅ５１ ) NR ｃ５１ R ｄ５１ , NR ｃ５１ C (=NR ｅ５１ ) NR ｃ５１ R ｄ５１ , NR ｃ５１ C (=NR ｅ５１ ) R ｂ５１ , NR ｃ５１ S(O)R ｂ５１ , NR ｃ５１ S(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ S(O) ２ R ｂ５１ , NR ｃ５１ S(O)(=NR ｅ５１ ) R ｂ５１ , NR ｃ５１ S(O) ２ NR ｃ５１ R ｄ５１ S(O)R ｂ５１ S(O)NR ｃ５１ R ｄ５１ , S(O) ２ R ｂ５１ , S(O) ２ NR ｃ５１ R ｄ５１ , OS(O)(=NR ｅ５１ ) R ｂ５１ OS(O) ２ R ｂ５１ SF ５ P(O)R ｆ５１ R ｇ５１ , OP(O)(OR ｈ５１ ) ( OR ｉ５１ ), P(O)(OR ｈ５１ ) ( OR ｉ５１ ), and BR ｊ５１ R ｋ５１ Selected independently from, the R ５Ａ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ｂ Optionally substituted with substituents, Each R ａ５１ , R ｃ５１ , and R ｄ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, Ｃ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ５１ , R ｃ５１ and R ｄ５１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ｂ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ５１ and R ｄ５１ However, together with the N atom to which they are bonded, they form a 5-10 member heteroaryl or 4-10 member heterocycloalkyl group, and the 5-10 member heteroaryl or 4-10 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. ５Ｂ Optionally substituted with substituents, Each R ｂ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ５１ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R groups. ５Ｂ Optionally substituted with substituents, Each R ｅ５１ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｆ５１ and R ｇ５１ However, H, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｈ５１ and R ｉ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R ｊ５１ and R ｋ５１ However, OH, C １～６ Alkoxy and C １～６ Selected independently from haloalkoxys, or any R bonded to the same B atom ｊ５１ and R ｋ５１ However, along with the aforementioned B atoms to which they are bonded, C １～６ Alkyl and C １～６ A 5- or 6-membered heterocycloalkyl group is formed, which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the haloalkyl group. Each R ５Ｂ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl-, (4-7 member heterocycloalkyl)-C １～６ Alkyl-, CN, NO ２ , OR ａ５２ , SR ａ５２ , NHOR ａ５２ , C(O)R ｂ５２ , C(O)NR ｃ５２ R ｄ５２ , C(O)NR ｃ５２ (OR ａ５２ ), C(O)OR ａ５２ OC(O)R ｂ５２ , OC(O)NR ｃ５２ R ｄ５２ , NR ｃ５２ R ｄ５２ , NR ｃ５２ NR ｃ５２ R ｄ５２ , NR ｃ５２ C(O)R ｂ５２ , NR ｃ５２ C(O)OR ａ５２ , NR ｃ５２ C(O)NR ｃ５２ R ｄ５２ , C(=NR ｅ５２ ) R ｂ５２ , C(=NR ｅ５２ ) NR ｃ５２ R ｄ５２ , NR ｃ５２ C (=NR ｅ５２ ) NR ｃ５２ R ｄ５２ , NR ｃ５２ C (=NR ｅ５２ ) R ｂ５２ , NR ｃ５２ S(O)R ｂ５２ , NR ｃ５２ S(O)NR ｃ５２ R ｄ５２ , NR ｃ５２ S(O) ２ R ｂ５２ , NR ｃ５２ S(O)(=NR ｅ５２ ) R ｂ５２ , NR ｃ５２ S(O) ２ NR ｃ５２ R ｄ５２ S(O)R ｂ５２ S(O)NR ｃ５２ R ｄ５２ , S(O) ２ R ｂ５２ , S(O) ２ NR ｃ５２ R ｄ５２ , OS(O)(=NR ｅ５２ ) R ｂ５２ , and OS(O) ２ R ｂ５２ Selected independently from, the R ５Ｂ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ａ５２ , R ｃ５２ , and R ｄ５２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ａ５２ , R ｃ５２ and R ｄ５２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ It can be optionally substituted with substituents, Alternatively, any R bonded to the same N atom ｃ５２ and R ｄ５２ However, together with the N atom to which they are bonded, they form a 5-6 member heteroaryl or 4-7 member heterocycloalkyl group, and the 5-6 member heteroaryl or 4-7 member heterocycloalkyl group consists of 1, 2, 3, or 4 independently selected R atoms. Ｍ Optionally substituted with substituents, Each R ｂ５２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently from alkyl, and R ｂ５２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. Ｍ Optionally substituted with substituents, Each R ｅ５２ However, H, OH, CN, C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkyl, C １～６ Haloalkoxy, C ２～６ Alkenil, C ２～６ Alkinyl, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C １～６ Alkyl-, C ３～７ Cycloalkyl-C １～６ Alkyl-, (5-6 member heteroaryl)-C １～６ Alkyl- and (4-7 member heterocycloalkyl)-C １～６ Selected independently of alkyl, Each R Ｍ However, H, OH, halo, oxo, CN, C(O)OH, NH ２ NO ２ SF ５ , C １～６ Alkyl, C １～６ Alkoxy, C １～６ Haloalkoxy, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, C ６～１０ Aryl-C １～６ Alkyl-, C ３～１０ Cycloalkyl-C １～６ Alkyl-, (5-10 member heteroaryl)-C １～６ Alkyl- and (4-10 member heterocycloalkyl)-C １～６ Selected independently of alkyl, However, the following: (i) Cy ４ However, it is not triazolopyridinil, (ii) R ５ However, not morpholinil or piperazinil, (iii) Cy ４ If R is phenyl, ５ is not pyridinyl or pyrimidinyl. The compound or a pharmaceutically acceptable salt thereof, provided that such a condition is met.

2. The compound of formula I is the compound of formula II: 【Chemistry 2】 or a pharmaceutically acceptable salt thereof, in the formula: R ４ However, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, OR ａ４ , and NR ｃ４ C(O)OR ａ４ Selected from, the R ４ C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ４Ａ Optionally substituted with substituents, Each R ａ４ , R ｃ４ , and R ｄ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ Selected independently from Alkinnil, Each R ４Ａ However, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl and CN are selected independently. R ５ However, triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, NR ｗ２ R ｗ３ , NR ｗ３ C(O)R ｗ２ , NR ｗ３ C(O)OR ｗ２ , and NR ｗ３ S(O) ２ R ｗ２ Selected from, the R ５ Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R ５Ａ Optionally substituted with substituents, Each R ｗ２ However, C ３～１２ A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, and the R ｗ２ C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ５Ａ Optionally substituted with substituents, Each R ｗ３ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ Selected independently from Alkinnil, Each R ５Ａ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, NO ２ , OR ａ５１ , SR ａ５１ , NHOR ａ５１ , C(O)R ｂ５１ , C(O)NR ｃ５１ R ｄ５１ , C(O)NR ｃ５１ (OR ａ５１ ), C(O)OR ａ５１ OC(O)R ｂ５１ , OC(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ R ｄ５１ , NR ｃ５１ NR ｃ５１ R ｄ５１ , NR ｃ５１ C(O)R ｂ５１ , NR ｃ５１ C(O)OR ａ５１ , NR ｃ５１ C(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ S(O)R ｂ５１ , NR ｃ５１ S(O)NR ｃ５１ R ｄ５１ , NR ｃ５１ S(O) ２ R ｂ５１ , NR ｃ５１ S(O) ２ NR ｃ５１ R ｄ５１ S(O)R ｂ５１ S(O)NR ｃ５１ R ｄ５１ , S(O) ２ R ｂ５１ , and S(O) ２ NR ｃ５１ R ｄ５１ Selected independently from, Each R ａ５１ , R ｂ５１ , R ｃ５１ , and R ｄ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ A compound according to claim 1, independently selected from alkynyl, or a pharmaceutically acceptable salt thereof.

3. R ４ However, phenyl, C ３～７ Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR ａ４ , and NR ｃ４ C(O)OR ａ４ Selected from, the R ４ Phenyl, C ３～７ Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. ４Ａ A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, optionally substituted with substituents.

4. R ４ However, phenyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, OR ａ４ , and NR ｃ４ C(O)OR ａ４ Selected from, the R ４ The phenyl, 5-6 member heteroaryl, and 4-7 member heterocycloalkyl groups are each independently selected from 1, 2, 3, or 4 R groups. ４Ａ A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, optionally substituted with substituents.

5. R ４ However, phenyl, tetrahydropyranyl, pyrazolyl, OR ａ４ , and NR ｃ４ C(O)OR ａ４ Selected from, the R ４ Phenyl, tetrahydropyranyl, and pyrazolyl are each 1, 2, 3, or 4 independently selected R ４Ａ Optionally substituted with substituents, Each R ａ４ and R ｃ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ A compound according to claim 1 or 2, independently selected from alkynyl, or a pharmaceutically acceptable salt thereof.

6. Each R ４Ａ However, C １～６ Alkyl, C １～６ A compound according to any one of claims 1 to 5, independently selected from haloalkyl and CN, or a pharmaceutically acceptable salt thereof.

7. Each R ４Ａ However, C １～６ A compound according to any one of claims 1 to 5, independently selected from alkyl and CN, or a pharmaceutically acceptable salt thereof.

8. Each R ４Ａ a compound according to any one of claims 1 to 5, independently selected from methyl and CN, or a pharmaceutically acceptable salt thereof.

9. R ４ However, phenyl, tetrahydropyranyl, pyrazolyl, OR ａ４ , and NR ｃ４ C(O)OR ａ４ Selected from, the R ４ Phenyl, tetrahydropyranyl, and pyrazolyl are each one or two independently selected R ４Ａ Optionally substituted with substituents, Each R ａ４ and R ｃ４ However, H and C １～６ Selected independently of alkyl, Each R ４Ａ However, C １～６ A compound according to claim 1 or 2, independently selected from alkyl and CN, or a pharmaceutically acceptable salt thereof.

10. R ５ However, triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, NHR ｗ２ NHC(O)R ｗ２ NHC(O)OR ｗ２ , and NHS(O) ２ R ｗ２ Selected from, the R ５ Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

11. Each R ｗ２ However, C ３～７ A cycloalkyl, a 5-6 member heteroaryl, and a 4-7 member heterocycloalkyl are independently selected, and the R ｗ２ C ３～７ Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. ５Ａ A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

12. Each R ｗ２ However, R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranil. ｗ２ Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R ５Ａ A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

13. Each R ５Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, CN, OR ａ５１ , C(O)R ｂ５１ , and C(O)OR ａ５１ Selected independently from, Each R ａ５１ and R ｂ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ A compound according to any one of claims 1 to 12, independently selected from alkynyl, or a pharmaceutically acceptable salt thereof.

14. Each R ５Ａ But, hello, C １～６ Alkyl and C(O)OR ａ５１ Selected independently from, Each R ａ５１ However, H and C １～６ A compound according to any one of claims 1 to 12, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

15. Each R ５Ａ a compound according to any one of claims 1 to 12, independently selected from fluoromethyl and ethoxycarbonyl, or a pharmaceutically acceptable salt thereof.

16. R ５ However, triazolyl, pyrazolyl, piperidinil, tetrahydropyranil, NHR ｗ２ NHC(O)R ｗ２ NHC(O)OR ｗ２ , and NHS(O) ２ R ｗ２ Selected from, the R ５ Triazolyl, pyrazolyl, piperidinyl, and tetrahydropyranil are each 1, 2, 3, or 4 independently selected R ５Ａ Optionally substituted with substituents, Each R ｗ２ However, R is independently selected from cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranil. ｗ２ Cyclopropyl, cyclobutyl, oxazolyl, and tetrahydropyranyl are each independently selected from 1, 2, 3, or 4 R ５Ａ Optionally substituted with substituents, Each R ５Ａ But, hello, C １～６ Alkyl and C(O)OR ａ５１ Selected independently from, Each R ａ５１ However, H and C １～６ A compound according to any one of claims 1 to 9, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

17. Cy ４ However, selected from thiazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, the Cy ４ Thiazolyl, pyrazolyl, pyridinyl, and pyrimidinyl are each 1, 2, 3, or 4 independently selected R ４ The compound according to claim 1, or a pharmaceutically acceptable salt thereof, optionally substituted with substituents.

18. The compound of formula I is a compound of formula IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, IIIk, IIIm, or IIin: 【Chemistry 3-1】 【Chemistry 3-2】 The compound according to claim 1 or 17, or a pharmaceutically acceptable salt thereof.

19. Each R ４ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, OR ａ４ , and C(O)R ｂ４ Selected independently from, the R ４ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ａ４ and R ｂ４ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Independently selected from alkynyls and 4-6 membered heterocycloalkyls, Each R ４Ａ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, OR ａ４１ , and C(O)R ｂ４１ Selected independently from, Each R ａ４１ and R ｂ４１ However, H, C １～６ Alkyl and C １～６ Selected independently from haloalkyl groups, R ５ However, C １～６ Alkyl, C ３～１２ Cycloalkyl, C ６～１０ Aryl, 5-12 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanil, OR ｗ２ , NR ｗ２ R ｗ３ , C(O)R ｗ２ , and C(O)NR ｗ２ R ｗ３ Selected from, The aforementioned R ５ C １～６ Alkyl and C ６～１０ Each aryl has one R ｗ１ The substituent and one or two independently selected R which may be optionally substituted. ５Ａ Substituting with a substituent, or The aforementioned R ５ C ６～１０ Aaryl is one R ｗ５ The substituent and one or two independently selected R which may be optionally substituted. ５Ａ Substituting with substituents, The aforementioned R ５ C ３～１２ Cycloalkyl, 5- to 12-membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R ５Ａ Optionally substituted with substituents, R ｗ１ However, C ３～１２ Cycloalkyl, 4-12 member heterocycloalkyl, OR ｗ４ , and NHR ｗ４ Selected from, the R ｗ１ C ３～１２ Each of the cycloalkyl and 4- to 12-membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. ５Ａ Optionally substituted by substituents, Each R ｗ２ However, C ３～１２ A cycloalkyl group is independently selected from 5-12 member heteroaryl groups and 4-12 member heterocycloalkyl groups, and the R ｗ２ C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, and 4-12 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ５Ａ Optionally substituted with substituents, Each R ｗ３ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ Selected independently from Alkinnil, Each R ｗ４ However, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Independently selected from cycloalkyl, 5-10 member heteroaryl, and 4-10 member heterocycloalkyl, R ｗ５ However, CN or OR ａ５１ C is replaced by １～６ It is alkyl, Each R ５Ａ However, halo, oxo, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, OR ａ５１ , and NR ｃ５１ R ｄ５１ Selected independently from, the R ５Ａ C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Alkinyl each has OR ａ５２ and optionally substituted with 1, 2, 3, 4, 5, 6, or 7 independently selected halo groups, Each R ａ５１ , R ｃ５１ , and R ｄ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ Selected independently from Alkinnil, Each R ａ５２ However, H and C １～６ A compound according to any one of claims 1, 17, and 18, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

20. Each R ４ But, hello, C １～６ Alkyl, C ６～１０ Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-10 member heterocycloalkyl)-C １～６ Alkyl-, OR ａ４ , and C(O)R ｂ４ Selected independently from, the R ４ C １～６ Alkyl, C ６～１０ Aryl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-10 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ａ４ and R ｂ４ However, H, C １～６ Alkyl, C １～６ A compound according to any one of claims 1 and 17 to 19, independently selected from haloalkyls and 4- to 6-membered heterocycloalkyls, or a pharmaceutically acceptable salt thereof.

21. Each R ４ But, hello, C １～６ Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, (4-6 member heterocycloalkyl)-C １～６ Alkyl-, OR ａ４ , and C(O)R ｂ４ Selected independently from, the R ４ C １～６ Alkyl, phenyl, 5-6 member heteroaryl, 4-10 member heterocycloalkyl, and (4-6 member heterocycloalkyl)-C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ａ４ and R ｂ４ However, C １～６ A compound according to any one of claims 1 and 17 to 19, independently selected from alkyl and 4- to 6-membered heterocycloalkyl groups, or a pharmaceutically acceptable salt thereof.

22. Each R ４ However, R is independently selected from fluoro, methyl, trideuterated methyl, isopropyl, methoxy, morpholinyl carbonyl, phenyl, pyrazolyl, pyridinyl, tetrahydropyranyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl, and ４ Methyl, isopropyl, phenyl, pyrazolyl, piperidinyl, and 2,3-dihydrobenzo[b][1,4]dioxynyl are each 1, 2, 3, or 4 independently selected R ４Ａ A compound according to any one of claims 1 and 17 to 19, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

23. Each R ４Ａ However, C １～６ Alkyl, C １～６ Haloalkyl, CN, OR ａ４１ , and C(O)R ｂ４１ Selected independently from, Each R ａ４１ and R ｂ４１ However, H and C １～６ A compound according to any one of claims 1 and 17 to 22, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

24. Each R ４Ａ The compound according to any one of claims 1 and 17 to 22, selected from methyl, difluoromethyl, trifluoromethyl, CN, OH, and methylcarbonyl, or a pharmaceutically acceptable salt thereof.

25. Each R ４ A compound according to any one of claims 1 and 17 to 19, which is independently selected from fluoro, methyl, hydroxymethyl, hydroxyisopropyl, methoxy, (methylcarbonyl)piperidinyl, methylpyrazolyl, cyanophenyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, (difluoromethylazetidinyl)methyl, and morpholinylcarbonyl, or a pharmaceutically acceptable salt thereof.

26. R ５ However, C １～６ Alkyl, C ３～７ Cycloalkyl, phenyl, 5-10 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, azaspiro[2,4]heptanyl, OR ｗ２ NHR ｗ２ , C(O)R ｗ２ , and C(O)NHR ｗ２ Selected from, The aforementioned R ５ C １～６ Alkyl and phenyl each have one R ｗ１ The substituent and one or two independently selected R which may be optionally substituted. ５Ａ Substituting with a substituent, or The aforementioned R ５ The phenyl has one R ｗ５ The substituent and one or two independently selected R which may be optionally substituted. ５Ａ Substituting with substituents, The aforementioned R ５ C ３～７ Cycloalkyl, 5-10 membered heteroaryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 and 17 to 25, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

27. R ５ However, -CH ２ R ｗ１ , C ３～７ Cycloalkyl, -phenyl-R ｗ１ , -phenyl-R ｗ５ , 5-10 member heteroaryl, tetrahydropyranil, pyrrolidinil, piperidinil, 2,3-dihydrobenzo[b][1,4]dioxynil, 3,4-dihydro-2H-benzo[b][1,4]oxazinil, azaspiro[2,4]heptanil, OR ｗ２ NHR ｗ２ , C(O)R ｗ２ , and C(O)NHR ｗ２ Selected from, the R ５ C ３～７ Cycloalkyl, phenyl, 5-10 membered heteroaryl, pyrrolidinyl, piperidinyl, 2,3-dihydrobenzo[b][1,4]dioxynyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, and azaspiro[2.4]heptanyl are each 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 and 17 to 25, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

28. R ｗ１ However, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, OR ｗ４ , and NHR ｗ４ Selected from, the R ｗ１ C ３～７ Each of the cycloalkyl and 4- to 7-membered heterocycloalkyl groups consists of one or two independently selected R groups. ５Ａ A compound according to any one of claims 1 and 17 to 27, or a pharmaceutically acceptable salt thereof, optionally substituted by a substituent.

29. R ｗ１ However, cyclopropyl, fluoropyrrolidinyl, morpholinyl, OR ｗ４ , and NHR ｗ４ Selected from, R ｗ４ However, C １～６ Haloalkyl and C ３～７ A compound according to any one of claims 1 and 17 to 27, selected from cycloalkyls, or a pharmaceutically acceptable salt thereof.

30. R ｗ１ The compound according to any one of claims 1 and 17 to 27, selected from cyclopropyl, fluoropyrrolidinyl, morpholinyl, trifluoromethoxy, and cyclopentylamino, or a pharmaceutically acceptable salt thereof.

31. R ｗ２ However, C ３～７ Selected from cycloalkyl, bicyclic 8-12 member heteroaryl, monocyclic 4-7 member heterocycloalkyl, and bicyclic 8-12 member heterocycloalkyl, the R ｗ２ C ３～７ Cycloalkyl, bicyclic 8-12 membered heteroaryl, monocyclic 4-7 membered heterocycloalkyl, and bicyclic 8-12 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 and 17 to 30, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

32. R ｗ２ However, it is selected from cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranil, piperidinil, morpholinil, pyrrolidinil, and octahydro-2H-pyrido[1,2-a]pyrazine, and the R ｗ２ Cyclobutyl, cyclopentyl, cyclohexyl, quinolinyl, tetrahydropyranil, piperidinyl, morpholinyl, pyrrolidinyl, and octahydro-2H-pyrido[1,2-a]pyradinyl are each 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 and 17 to 30, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

33. R ｗ５ However, CN or OR ａ５１ C is replaced by １～６ It is alkyl, R ａ５１ However, H and C １～３ A compound according to any one of claims 1 and 17 to 32, selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

34. R ｗ５ The compound according to any one of claims 1 and 17 to 32, selected from cyanomethyl and hydroxymethyl, or a pharmaceutically acceptable salt thereof.

35. Each R ５Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, CN, OR ａ５１ , and NR ｃ５１ R ｄ５１ Selected independently from, C １～６ The alkyl group is optionally substituted with an OH group and one, two, three, four, five, six, or seven independently selected halo groups. Each R ａ５１ , R ｃ５１ , and R ｄ５１ However, H and C １～６ A compound according to any one of claims 1 and 17 to 34, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

36. Each R ５Ａ A compound according to any one of claims 1 and 17-34, independently selected from chloro, fluoro, methyl, hydroxyisopropyl, hydroxyhexafluoroisopropyl, difluoromethyl, trifluoromethyl, CN, methoxy, ethoxy, and amino, or a pharmaceutically acceptable salt thereof.

37. Cy ４ R is selected from quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl, and each of the quinolinyl, imidazo[1,2-b]pyridazinyl, and pyrazolo[1,5-a]pyrimidinyl is selected in 1, 2, 3, or 4 independent ways. ４ The compound according to claim 1, or a pharmaceutically acceptable salt thereof, optionally substituted with substituents.

38. The compound of formula I is a compound of formula IVa, IVb, IVC, IVd, IVe, IVf, IVg, IVh, IVi, IVj, IVk, IVm, IVn, IVo, IVp, IVq, IVr, IVs, IVt, IVu, or IVv: 【Chemistry 4-1】 【Chemistry 4-2】 【Chemistry 4-3】 The compound according to claim 1 or 37, or a pharmaceutically acceptable salt thereof.

39. Each R ４ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ Selected independently of alkyl, R ４ Each C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ The alkyl group consists of 1, 2, 3, or 4 independently selected R groups. ４Ａ Optionally substituted with substituents, Each R ４Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, and OR ａ４１ Selected independently from, Each R ａ４１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ Selected independently from Alkinnil, R ５ However, C ３～１２ Cycloalkyl, 5-12 membered heteroaryl, NR ｗ２ R ｗ３ , and C(O)R ｗ２ Selected from, the R ５ C ３～１２ Each of the cycloalkyl and 5-12 membered heteroaryl groups consists of 1, 2, 3, or 4 independently selected R groups. ５Ａ Optionally substituted with substituents, Each R ｗ２ However, C ３～１２ Independently selected from cycloalkyl and 4- to 12-membered heterocycloalkyl, the R ｗ２ C ３～１２ Each of the cycloalkyl and 4- to 12-membered heterocycloalkyl groups consists of 1, 2, 3, or 4 independently selected R groups. ５Ａ Optionally substituted with substituents, Each R ｗ３ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl, or C ２～６ Selected independently from Alkinnil, Each R ５Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, and OR ａ５１ Selected independently from, Each R ａ５１ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenyl and C ２～６ A compound according to any one of claims 1, 37, and 38, independently selected from alkynyl, or a pharmaceutically acceptable salt thereof.

40. R ４ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ Selected independently of alkyl, R ４ Each C １～６ Alkyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ The alkyl group consists of 1, 2, 3, or 4 independently selected R groups. ４Ａ A compound according to any one of claims 1 and 37 to 39, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

41. R ４ However, C １～６ Alkyl, C １～６ Haloalkyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ Selected independently of alkyl, R ４ Each C １～６ Alkyl, C ３～７ Cycloalkyl, 4-7 member heterocycloalkyl, 5-6 member heteroaryl, and C ３～７ Cycloalkyl-C １～６ Alkyl- has 1, 2, 3, or 4 R's. ４Ａ Optionally substituted with substituents, Each R ４Ａ However, C １～６ Haloalkyl, CN, and OR ａ４１ Selected independently from, Each R ａ４１ However, H and C １～６ A compound according to any one of claims 1 and 37-39, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

42. R ４ However, R is selected from methyl, ethyl, isopropyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterated tetrahydropyranyl, pyridinyl, and cyclopropylmethyl. ４ Each of the following is methyl, ethyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl, cyclohexyl, tetrahydropyranyl, deuterated tetrahydropyranyl, pyridinyl, and cyclopropylmethyl, C １～３ Haloalkyl, CN, OH, and C １～３ One or two R selected independently of the alkoxy ４Ａ A compound according to any one of claims 1 and 37 to 39, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

43. R ５ However, C ３～７ Cycloalkyl, 5-6 member heteroaryl, NHR ｗ２ , and C(O)R ｗ２ Selected from, the R ５ C ３～７ Each of the cycloalkyl and 5-6 membered heteroaryl groups consists of 1, 2, 3, or 4 independently selected R groups. ５Ａ A compound according to any one of claims 1 and 37 to 42, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

44. R ５ However, cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, pyridinyl, NHR ｗ２ , and C(O)R ｗ２ Selected from, the R ５ Cyclopropyl, cyclobutyl, cyclohexyl, pyrazolyl, imidazolyl, and pyridinyl are each independently selected from 1, 2, 3, or 4 R ５Ａ A compound according to any one of claims 1 and 37 to 42, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

45. R ｗ２ However, C ３～７ Selected from cycloalkyl, 4-8 membered monocyclic heterocycloalkyl, and 6-10 membered bicyclic heterocycloalkyl, the R ｗ２ C ３～７ Cycloalkyls, 4-8 membered monocyclic heterocycloalkyls, and 6-10 membered bicyclic heterocycloalkyls each have 1, 2, 3, or 4 independently selected R ５Ａ A compound according to any one of claims 1 and 37 to 44, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

46. R ｗ２ However, selected from cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl, the R ｗ２ Cyclopentyl, piperidinyl, morpholinyl, 1,6-diazaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, and 2-oxa-5-azabicyclo[4.1.0]heptanyl are each selected from 1, 2, 3, or 4 independently R ５Ａ A compound according to any one of claims 1 and 37 to 44, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

47. Each R ５Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, CN, and OR ａ５１ Selected independently from, Each R ａ５１ However, H and C １～６ A compound according to any one of claims 1 and 37 to 46, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

48. Each R ５Ａ A compound according to any one of claims 1 and 37 to 46, independently selected from fluoromethyl, trideuterated methyl, difluoromethyl, trifluoromethyl, CN, and hydroxy, or a pharmaceutically acceptable salt thereof.

49. R １ However, one, two, or three independently selected R １Ａ C which can be arbitrarily substituted with substituents １～６ A compound according to any one of claims 1 to 48, which is alkyl, or a pharmaceutically acceptable salt thereof.

50. R １ However, C １～６ A compound according to any one of claims 1 to 49, which is alkyl, or a pharmaceutically acceptable salt thereof.

51. R １ The compound according to any one of claims 1 to 49, wherein the compound is methyl or methyl trideuteride, or a pharmaceutically acceptable salt thereof.

52. Cy ２ However, single ring type C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, the monocyclic C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R ２ A compound according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, substituted with a substituent.

53. Cy ２ However, selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil, the Cy ２ Cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil are each one, two, three, or four independently selected R ２ A compound according to any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, optionally substituted by substituents.

54. Cy ２ but, 【Transformation 5】 Selected from, A compound according to any one of claims 1 to 51, wherein n is 0, 1, or 2, or a pharmaceutically acceptable salt thereof.

55. Cy ２ but, 【Chemistry 6-1】 【Chemistry 6-2】 A compound according to any one of claims 1 to 51, selected from, or a pharmaceutically acceptable salt thereof.

56. Cy ２ but, 【Chemistry 7-1】 【Chemistry 7-2】 A compound according to any one of claims 1 to 51, selected from, or a pharmaceutically acceptable salt thereof.

57. Each R ２ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ R ｄ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , NR ｃ２ C(O)NR ｃ２ R ｄ２ , NR ｃ２ S(O)R ｂ２ , NR ｃ２ S(O) ２ R ｂ２ S(O)R ｂ２ S(O)NR ｃ２ R ｄ２ , S(O) ２ R ｂ２ , and S(O) ２ NR ｃ２ R ｄ２ Selected independently from, the R ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Each alkynyl is one, two, three, or four independently selected R ２Ａ A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

58. Each R ２ But, hello, C １～６ Alkyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , and NR ｃ２ S(O) ２ R ｂ２ Selected independently from, the R ２ C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R ２Ａ A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

59. Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ２Ａ A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

60. Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H, C １～６ Alkyl, C ２～６ Alkinyl, phenyl, C ３～７ A cycloalkyl, a 5-6 member heteroaryl, and a 4-7 member heterocycloalkyl are independently selected, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ C １～６ Alkyl, phenyl, C ３～７ Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. ２Ａ A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

61. Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H is independently selected from methyl, trideuterated methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ Methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R ２Ａ A compound according to any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

62. Each R ２ But, hello, C １～６ Alkyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , and NR ｃ２ S(O) ２ R ｂ２ Selected independently from, the R ２ C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R ２Ａ Optionally substituted with substituents, Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H is independently selected from methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ Methyl, trideuterated methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each one or two independently selected R ２Ａ A compound according to any one of claims 1 to 56, or a pharmaceutically acceptable salt thereof, optionally substituted with a substituent.

63. Each R ２Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, and OR ａ２１ A compound according to any one of claims 1 to 62, or a pharmaceutically acceptable salt thereof, independently selected from the above.

64. Each R ２Ａ However, halo and OR ａ２１ Selected independently from, Each R ａ２１ However, H and C １～６ A compound according to any one of claims 1 to 62, independently selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

65. Each R ２Ａ a compound according to any one of claims 1 to 62, independently selected from fluoro, hydroxy, and methoxy, or a pharmaceutically acceptable salt thereof.

66. R ３ However, H and C １～６ A compound according to any one of claims 1 to 65, selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

67. R ３ A compound according to any one of claims 1 to 65, wherein is H, or a pharmaceutically acceptable salt thereof.

68. R １ However, C １～６ Alkyl, C ２～６ Alkenyl and C ２～６ Selected from Alkinir, Cy ２ However, single ring type C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, the monocyclic C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R ２ Substituting with substituents, Each R ２ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ R ｄ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , NR ｃ２ C(O)NR ｃ２ R ｄ２ , NR ｃ２ S(O)R ｂ２ , NR ｃ２ S(O) ２ R ｂ２ S(O)R ｂ２ S(O)NR ｃ２ R ｄ２ , S(O) ２ R ｂ２ , and S(O) ２ NR ｃ２ R ｄ２ Selected independently from, the R ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Each alkynyl is one, two, three, or four independently selected R ２Ａ Optionally substituted with substituents, Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ A cycloalkyl group is independently selected from cycloalkyl groups, 5-10 member heteroaryl groups, and 4-10 member heterocycloalkyl groups, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ C １～６ Alkyl, C ２～６ Alkenil, C ２～６ Alkinyl, C ６～１０ Ariel, C ３～１０ Cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl each have 1, 2, 3, or 4 independently selected R ２Ａ Optionally substituted with substituents, Each R ２Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, and OR ａ２１ Selected independently from, Each R ａ２１ However, H and C １～６ Selected independently of alkyl, R ３ However, H and C １～６ A compound according to any one of claims 1 to 48, selected from alkyl groups, or a pharmaceutically acceptable salt thereof.

69. R １ However, C １～６ Selected from alkyl groups, Cy ２ However, single ring type C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Selected from cycloalkyl, monocyclic 4-7 membered heterocycloalkyl, spirocyclic 6-10 membered heterocycloalkyl, and bicyclic 5-10 membered heterocycloalkyl, the monocyclic C ３～１０ Cycloalkyl, bicyclic C ６～１０ Cycloalkyl, spirocyclic C ６～１０ Cycloalkyls, monocyclic 4-7 membered heterocycloalkyls, spirocyclic 6-10 membered heterocycloalkyls, and bicyclic 5-10 membered heterocycloalkyls each have 1, 2, 3, or 4 independently selected R ２ Substituting with substituents, Each R ２ But, hello, C １～６ Alkyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , and NR ｃ２ S(O) ２ R ｂ２ Selected independently from, the R ２ C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R ２Ａ Optionally substituted with substituents, Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H, C １～６ Alkyl, C ２～６ Alkinyl, phenyl, C ３～７ A cycloalkyl, a 5-6 member heteroaryl, and a 4-7 member heterocycloalkyl are independently selected, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ C １～６ Alkyl, phenyl, C ３～７ Cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each selected from 1, 2, 3, or 4 independently. ２Ａ Optionally substituted with substituents, Each R ２Ａ But, hello, C １～６ Alkyl, C １～６ Haloalkyl, C ２～６ Alkenil, C ２～６ Alkinyl, CN, and OR ａ２１ Selected independently from, Each R ａ２１ However, H and C １～６ Selected independently of alkyl, R ３ A compound according to any one of claims 1 to 48, wherein is H, or a pharmaceutically acceptable salt thereof.

70. R １ However, C １～３ It is alkyl, Cy ２ However, selected from cyclobutyl, cyclopentyl, deuterated cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil, the Cy ２ Cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranil, bicyclo[2.2.1]heptanil, bicyclo[2.2.2]octanil, spiro[3.3]heptanil, 3-azabicyclo[3.1.0]hexanil, 2-azaspiro[3.3]heptanil, and 2-azabicyclo[2.2.1]heptanil are each one, two, three, or four independently selected R ２ Optionally substituted by substituents, Each R ２ But, hello, C １～６ Alkyl, CN, OR ａ２ , C(O)R ｂ２ , C(O)NR ｃ２ R ｄ２ , C(O)OR ａ２ , NR ｃ２ C(O)R ｂ２ , NR ｃ２ C(O)OR ａ２ , and NR ｃ２ S(O) ２ R ｂ２ Selected independently from, the R ２ C １～６ Each alkyl group consists of 1, 2, 3, or 4 independently selected R ２Ａ Optionally substituted with substituents, Each R ａ２ , R ｂ２ , R ｃ２ , and R ｄ２ However, H is independently selected from methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl, and the R ａ２ , R ｂ１ , R ｃ２ , and R ｄ２ Methyl, trideuterated methyl, ethyl, propynyl, cyclopropyl, cyclobutyl, phenyl, and tetrahydropyranyl are each 1, 2, 3, or 4 independently selected R ２Ａ Optionally substituted with substituents, Each R ２Ａ However, halo and OR ａ２１ Selected independently from, Each R ａ２１ However, H and C １～６ Selected independently of alkyl, R ３ A compound according to any one of claims 1 to 48, wherein is H, or a pharmaceutically acceptable salt thereof.

71. 2-((3'-cyano-5-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-[1,1'-biphenyl]-3-yl)amino)oxazole-5-carboxylate ethyl, ((1R,3R)-3-(6-((3'-cyano-5-(4-fluorotetrahydro-2H-pyran-4-carboxamide)-[1,1'-biphenyl]-3-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((4-(1-methyl-1,6-diazaspiro[3.3]heptan-6-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-(hydroxymethyl)-3-methylphenyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6'-methoxy-[2,3'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(4-cyanopiperidine-1-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(3-methyl-1H-indazole-5-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(quinoline-6-yl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(1-hydroxy-3-azabicyclo[3.1.0]hexane-3-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-oxa-5-azabicyclo[2.2.1]heptan-5-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-oxa-5-azabicyclo[4.1.0]heptan-5-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-1,2,3-triazole-4-yl)phenyl)methyl carbamate, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methylpiperidine-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((4-(3,3-difluoropiperidine-1-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((R)-2,2-difluorocyclopropane-1-carboxamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-((3,3-difluorocyclopentyl)amino)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(cyclobutanecarboxamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((6-(1-methyl-1H-pyrazole-4-yl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1R,3R)-3-((methoxycarbonyl)amino)cyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(tetrahydro-2H-pyran-3-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((6-((4-cyanocyclohexyl)oxy)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(quinoline-6-yloxy)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-((1r,3r)-3-(cyclopropanecarboxamide)cyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (3-((1-(6-((ethoxycarbonyl)amino)spiro[3.3]heptan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (3-((1-(6-(cyclopropanesulfonamide)spiro[3,3]heptan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, 6-(6-((3-(((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-2-azaspiro[3.3]heptan-2-carboxylate methyl, (3-((1-((1r,3r)-3-cyanocyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (3-((1-((1r,3r)-3-((methoxycarbonyl)amino)-3-methylcyclobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (R)-(3-((1-(3,3-difluorocyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, (3-((1-((1R,3S)-3-fluorocyclopentyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((6-(1-methyl-1H-pyrazole-4-yl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((8-(1-methyl-1H-pyrazole-4-yl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-pyrazole-4-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((2-(1-methyl-1H-pyrazole-4-yl)pyrazolo[1,5-a]pyrimidine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-pyrazole-4-yl)pyrazolo[1,5-a]pyrimidine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-((tetrahydro-2H-pyran-4-yl)oxy)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-6-((3-(1-methyl-1H-imidazole-5-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (1R,5S)-6-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-3-azabicyclo[3.1.0]hexane-3-carboylate methyl, (3-((1-(2-acetyl-2-azabicyclo[2.2.1]heptan-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((3-((3,3-difluorocyclobutane)-1-sulfonamide)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, (3-((1-(4-((methoxycarbonyl)amino)-4-methylcyclohexyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate 2-methoxyethyl, ((1R,3R)-3-(6-((3-(cyclobutoxycarbonyl)amino)-5-(tetrahydro-2H-pyran-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclobutyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)ethyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate propane-2-in-1-yl, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate tetrahydro-2H-pyran-4-yl, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate 4-fluorophenyl, ((1R,3R)-3-(6-((6-cyclopropylpyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(3-cyanophenyl)-4-(1-methyl-1H-pyrazole-4-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((methoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-cyclopropylimidazo[1,2-b]pyridazine-6-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclopropoxycarbonyl)amino)-5-methoxyphenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-((cyclobutoxycarbonyl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(cyclopropanecarboxamide)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((8-(1-methylcyclopropyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(3-fluoro-1-(methyl-d ３ )-1H-pyrazole-4-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(cyclobutoxymethyl)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(3-aminopyrrolidine-1-yl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-((cyclopentylamino)methyl)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-(piperidine-1-yl)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2'-methoxy-4-methyl-[2,4'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((4-(pyridine-4-yl)thiazole-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-fluoro-6'-(trifluoromethyl)-[2,3'-bipyridine]-6-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(((S)-3-fluoropyrrolidine-1-yl)methyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-(cyanomethyl)phenyl)-5-fluoropyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(4-cyclopropylphenyl)-5-fluoropyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((5-fluoro-6-(4-(trifluoromethoxy)phenyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(morpholinomethyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(2-methoxypyridine-4-yl)pyrimidine-4-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(octahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(5-azaspiro[2,4]heptan-5-yl)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(3,3-difluoropyrrolidine-1-yl)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-(4-(trifluoromethyl)piperidine-1-yl)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-((R)-3-fluoropyrrolidine-1-carbonyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((1-(pyridine-4-yl)-1H-pyrazole-3-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-((3,3-difluorocyclopentyl)amino)pyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(3,3-difluoropyrrolidine-1-yl)-6-methylpyrimidine-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidine-4-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(3-methyl-2-oxo-6-((6-(piperidine-1-carbonyl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)carbamate methyl, and ((1R,3R)-3-(6-((6-(cyclohexylcarbamoyl)pyridine-2-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, The compound according to claim 1, or selected from a pharmaceutically acceptable salt thereof.

72. It is a compound, (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-methyl-1H-pyrazole-4-yl)phenyl)cyclobutyl carbamate, (3-((1-cyclopentyl-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)-5-(1-cyclopropyl-1H-pyrazole-4-yl)phenyl)cyclobutyl carbamate, and (3-(1-cyclopropyl-1H-pyrazole-4-yl)-5-((3-methyl-2-oxo-1-(tetrahydrofuran-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-6-yl)amino)phenyl)cyclobutyl carbamate, The compound, or selected from a pharmaceutically acceptable salt thereof.

73. ((1R,3R)-3-(6-((1-(2-methoxyethyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-1-methyl-2-oxo-7-(4-(trifluoromethyl)pyridine-3-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-(6-(3-(methyl-d ３ )-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)spiro[3,3]heptan-2-yl)cyclopropanecarboxamide, N-((1s,4s)-1-methyl-4-(3-(methyl-d ３ )-6-((2-methyl-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclohexyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((6-(5-chlorothiazole-2-yl)-4-(2-hydroxypropan-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((6-(5-chlorothiazol-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(1-methyl-1H-pyrazole-4-yl)-8-(trifluoromethyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((8-(2-cyanopropane-2-yl)-4-(morpholine-4-carbonyl)quinoline-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-3-d)methyl carbamate, ((1R,3R)-3-(6-((5-methoxy-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-((3-(difluoromethyl)azetidine-1-yl)methyl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-cyclobutoxy-5-(1-methyl-1H-pyrazole-4-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((2-(5-(difluoromethyl)thiophen-2-yl)-6-(hydroxymethyl)pyrimidine-4-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(difluoromethyl)thiophen-2-yl)-4-(morpholine-4-carbonyl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(1-acetylpiperidine-4-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, 6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-1-((1r,3r)-3-(2-hydroxypropane-2-yl)cyclobutyl)-3-(methyl-d ３ )-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(1-methyl-1H-pyrazole-4-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, and ((1R,3R)-3-(3-(methyl-d ３ )-2-oxo-6-((6-(4-(trifluoromethyl)-1H-pyrazole-1-yl)pyridine-2-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, The compound according to claim 1, or selected from a pharmaceutically acceptable salt thereof.

74. ((1R,3R)-3-(3-(methyl-d ３ )-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((3R)-3-(3-(methyl-d ３ )-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(3-(methyl-d ３ )-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl-4-d)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-(1-cyanocyclopropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-7-(2-hydroxypropan-2-yl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1R,3R)-1-methyl-3-(3-(methyl-d ３ )-6-((4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((7-(hydroxymethyl)-2-methyl-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, N-((1s,4s)-4-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide, N-((1S,3R)-3-(6-((2-((1s,3s)-3-hydroxycyclobutyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((1R,3R)-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((2-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)cyclopropanecarboxamide, ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1s,4s)-4-(6-((1-((1r,4r)-4-hydroxycyclohexyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclohexyl)cyclopropanecarboxamide, N-((1s,4s)-1-methyl-4-(3-(methyl-d ３ )-6-((2-methyl-7-(morpholine-4-carbonyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclohexyl)cyclopropanecarboxamide, ((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((1-(2-hydroxy-2-methylpropyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((3R)-3-(6-((7-(2-hydroxypropan-2-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[3,2-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((4-(2-hydroxypropan-2-yl)-1-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrrolo[2,3-b]pyridine-6-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(3-(methyl-d ３ )-2-oxo-6-((1-(tetrahydro-2H-pyran-4-yl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((1-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-1H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((3R)-3-(6-((2-((1-cyanocyclopropyl)methyl)-3-(1-(trifluoromethyl)-1H-pyrazole-4-yl)-2H-pyrazolo[4,3-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((6-methyl-4-(morpholine-4-carbonyl)-8-(trifluoromethyl)quinoline-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((6-(5-chlorothiazole-2-yl)-4-(2-hydroxypropan-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-N-(methyl-d ３ ) Bicyclo[2.2.2]octane-1-carboxamide, N-cyclopropyl-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octane-1-carboxamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octane-1-carboxamide, N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.2]octan-1-yl)acetamide, 4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.1]heptan-1-carboxamide, N-(4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)bicyclo[2.2.1]heptan-1-yl)acetamide, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)propionamide, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2-yl)thiazole-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-(trifluoromethyl)thiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((1R,3R)-3-(6-((6-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropane-2-yl)thiazole-2-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((5-fluoro-6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-methylpyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(methyl-d ３ (Pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-isopropoxythiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, N-((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(2-methoxythiazole-5-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, N-((1S,3R)-3-(6-((6-(2-ethoxythiazole-5-yl)-4-(2-hydroxypropane-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, ((1R,3R)-3-(6-((6'-(5-(difluoromethyl)thiophen-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1S,2S,4S)-2-hydroxy-4-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-3-d)methyl carbamate, ((1R,3R)-3-(3-(methyl-d ３ )-6-((4-(1-methylpiperidine-4-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((4-(2-hydroxypropan-2-yl)-6-(5-(trifluoromethyl)thiazole-2-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((6-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(tetrahydro-2H-pyran-4-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6'-(5-(2-hydroxypropane-2-yl)thiazole-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1S,3R)-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-4-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6-(5-(2-hydroxypropane-2-yl)thiazole-2-yl)-4-(1-methylpiperidine-4-yl)pyridine-2-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, ((1R,3R)-3-(6-((6'-(5-(2-hydroxypropan-2-yl)thiazole-2-yl)-2-(trifluoromethyl)-[3,4'-bipyridine]-2'-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, N-((1S,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-2-methyl-8-(4-(trifluoromethyl)pyridine-3-yl)imidazo[1,2-b]pyridazine-6-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)-1-methylcyclopentyl)acetamide, and ((1R,3R)-3-(6-((3-(1-(difluoromethyl)-1H-pyrazole-4-yl)-7-(2-hydroxypropan-2-yl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-yl)amino)-3-(methyl-d ３ )-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridine-1-yl)cyclopentyl-1-d)methyl carbamate, The compound according to claim 1, or selected from a pharmaceutically acceptable salt thereof.

75. The compound according to any one of claims 1 to 74, or a pharmaceutically acceptable salt thereof, wherein the compound is deuterated.

76. A pharmaceutical composition comprising a compound according to any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

77. A method for inhibiting the V617F variant activity of JAK2 kinase, comprising contacting the kinase with a compound according to any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

78. A method for treating cancer in a patient requiring cancer treatment, comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

79. The method according to claim 78, wherein the cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, testicular cancer, uterine cancer, vulvar cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, parathyroid cancer, neuroendocrine cancer, skin cancer, and brain cancer.

80. The method according to claim 78, wherein the cancer is a blood cancer.

81. The method according to claim 78, wherein the cancer is selected from leukemia, lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, acute myeloid leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin or non-Hodgkin lymphoma, myeloproliferative neoplasm, myelodysplastic syndrome, chronic eosinophilic leukemia, Waldenström macroglobulinemia, hairy cell lymphoma, chronic myeloid lymphoma, acute lymphoblastic lymphoma, AIDS-associated lymphoma, and Burkitt lymphoma.

82. A method for treating a myeloproliferative disorder in a patient requiring treatment for the myeloproliferative disorder, comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

83. The method according to claim 82, wherein the myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, primary myelofibrosis, myelofibrosis progressing from essential thrombocythemia, myelofibrosis progressing from polycythemia vera, chronic myeloid leukemia, chronic myelomonocytic leukemia, eosinophilic syndrome, and systemic mastocytosis.

84. A method for treating myelodysplastic syndrome in a patient requiring treatment for myelodysplastic syndrome, comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof.

Images